An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 in Children with Growth Failure Due to Lysosomal Acid Lipase Deficiency

Unique Protocol ID: LAL-CL03
NCT Number: NCT01371825
EudraCT Number: 2011-000032-28
Date of Protocol: 05 January 2016
AN OPEN LABEL, MULTICENTER, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SBC-102 IN CHILDREN WITH GROWTH FAILURE DUE TO LYSOSOMAL ACID LIPASE DEFICIENCY

Protocol Number: LAL-CL03
Date of Protocol: 05 January 2016
Amendment: 12.0
Product: Sebelipase alfa (SBC-102)
IND No.: 108460
EUDRACT No.: 2011-000032-28

Sponsor: Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410
USA

<table>
<thead>
<tr>
<th>Amendment History</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol</td>
</tr>
<tr>
<td>Original</td>
</tr>
<tr>
<td>Amendment 1</td>
</tr>
<tr>
<td>Amendment 2 (country-specific: France)</td>
</tr>
<tr>
<td>Amendment 3</td>
</tr>
<tr>
<td>Amendment 4 (country-specific: France)</td>
</tr>
<tr>
<td>Amendment 5 (country-specific: Germany)</td>
</tr>
<tr>
<td>Amendment 6</td>
</tr>
<tr>
<td>Amendment 7</td>
</tr>
<tr>
<td>Amendment 8</td>
</tr>
<tr>
<td>Amendment 9</td>
</tr>
<tr>
<td>Amendment 10</td>
</tr>
<tr>
<td>Amendment 10 (country-specific: France)</td>
</tr>
<tr>
<td>Amendment 11</td>
</tr>
<tr>
<td>Amendment 12.0</td>
</tr>
</tbody>
</table>
PROTOCOL SIGNATURE PAGE

Protocol title: An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 in Children with Growth Failure Due to Lysosomal Acid Lipase Deficiency

Protocol Number: LAL-CL03

Date of Protocol: 05 January 2016

Amendment: 12.0

Product: Sebelipase alfa (SBC-102)

IND No.: 108460

EUDRACT No.: 2011-000032-28

Sponsor: Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410
USA

PPD

Alexion Pharmaceuticals, Inc.

Date

05 JAN 2016

Page 2 of 76

ALEXION PHARMACEUTICALS, INC. PROPRIETARY AND CONFIDENTIAL:
DO NOT COPY OR DISTRIBUTE WITHOUT PERMISSION
PROTOCOL SIGNATURE PAGE

Protocol title: An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 in Children with Growth Failure Due to Lysosomal Acid Lipase Deficiency

Protocol Number: LAL-CL03

Date of Protocol: 05 January 2016

Amendment: 12.0

Product: Sebelipase alfa (SBC-102)

IND No.: 108460

EUDRACT No.: 2011-000032-28

Sponsor: Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410
USA

PPD

Date

Alexion Pharmaceuticals, Inc.
INVESTIGATOR AGREEMENT

I agree to conduct this clinical study in accordance with the design and specific provisions of this protocol and will only make changes in the protocol after notifying the Sponsor.

I understand that I may terminate or suspend enrolment of the study at any time if it becomes necessary to protect the best interests of the study subjects. This study may be terminated by the Sponsor, with or without cause.

I agree to personally conduct or supervise this investigation and to ensure that all associates, colleagues, and employees assisting in the conduct of this study are informed about their obligations in meeting these commitments.

I will conduct the study in accordance with Good Clinical Practice, the Declaration of Helsinki, and the moral, ethical and scientific principles that justify medical research. The study will be conducted in accordance with all relevant laws and regulations relating to clinical studies and the protection of subjects.

I will ensure that the requirements relating to Institutional Review Boards/Independent Ethics Committees (IRB/IEC) review and approval are met. I will provide the Sponsor with any material which is provided to the IRB/IEC for ethical approval.

I agree to maintain adequate and accurate records and to make those records available for audit and inspection in accordance with relevant regulatory requirements.

I agree to promptly report to the IRB/IEC any changes in the research activity and all unanticipated problems involving risks to human subjects or others. Additionally, I will not make any changes in the research without IRB/IEC approval, except where necessary to ensure the safety of study participants.

Print Name ___________________________________________ Institution __________________________

Signature _______________________________ Date ___________________________
## Protocol Synopsis

### Summary of planned clinical study

<table>
<thead>
<tr>
<th>Protocol Number (study identifier)</th>
<th>LAL-CL03</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title</strong></td>
<td>An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 in Children with Growth Failure Due to Lysosomal Acid Lipase Deficiency</td>
</tr>
</tbody>
</table>

| Study design features | This is an open-label, repeat-dose, dose escalation study of SBC-102 (USAN: sebelipase alfa) in children with growth failure due to LAL Deficiency. Eligible subjects will receive once-weekly (qw) infusions of sebelipase alfa for up to 5 years. Subjects who are on treatment for at least 96 weeks and are on a stable dose for at least 24 weeks may be considered to transition to an every other week dosing schedule. All subjects will initiate treatment at a dose of 0.35 mg/kg qw. Dose escalation to 1 mg/kg qw will occur in all subjects, contingent upon acceptable safety and tolerability, and a further dose escalation to 3 mg/kg qw may be permitted in subjects who meet defined criteria. All subjects will be evaluated for safety, tolerability, and efficacy. Where feasible, given blood volume thresholds based on subject weight, blood samples will also be collected for analyses of the pharmacokinetics (PK) and pharmacodynamics (PD) of sebelipase alfa and for an exploratory analysis of potential disease-related biomarkers in this patient population. |

| Background (rationale) | Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lipid storage disorder that is caused by a marked decrease or almost complete absence of LAL, leading to the accumulation of lipids, predominately cholesteryl esters and triglycerides, in various tissues and cell types. In the liver, accumulation of lipids leads to hepatomegaly, liver dysfunction, and hepatic failure. In the small intestine, lipid-laden macrophage accumulation in the lamina propria leads to profound malabsorption. LAL Deficiency presenting in infancy is an extremely rare form of LAL Deficiency that is usually fatal within the first 6 months of life (Assmann, 2001, *The Metabolic and Molecular Basis of Inherited Disease*). It is characterized by profound malabsorption, growth failure, and hepatic failure. There is currently no safe or effective therapy for the treatment of LAL Deficiency. |

| Main objective(s) | The primary objective of the study is to evaluate the effect of sebelipase alfa therapy on survival at 12 months of age in children with growth failure due to LAL Deficiency. The secondary objectives are (1) to evaluate the safety and tolerability of sebelipase alfa in children with growth failure due to LAL Deficiency; (2) to evaluate the effect of sebelipase alfa therapy on survival beyond 12 months of age in children with growth failure due to LAL Deficiency; (3) to evaluate the effects of sebelipase alfa on growth parameters in children with growth failure due to LAL Deficiency; (4) to evaluate the effects of sebelipase alfa on hepatomegaly, splenomegaly, and liver function in children with growth failure due to LAL Deficiency; (5) to determine the effects of sebelipase alfa on hematological parameters in children with growth failure due to LAL Deficiency; and (6) to characterize the PK of sebelipase alfa delivered by |
intravenous (IV) infusion.

The exploratory objectives are (1) to determine the effects of sebelipase alfa on lipid parameters in children with growth failure due to LAL Deficiency; (2) to assess the effects of sebelipase alfa on achievement of developmental milestones in children with growth failure due to LAL Deficiency; (3) to assess the effects of sebelipase alfa on the ability of children with LAL Deficiency to tolerate an unrestricted diet; and (4) to evaluate potential disease-related biomarkers.

<table>
<thead>
<tr>
<th>Study population and subset definition</th>
<th>The study population is children with growth failure due to LAL Deficiency.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of study participants (e.g. age, sex, severity)</td>
<td>Approximately 10 subjects will be enrolled in this study, including a minimum of 8 subjects who are 8 months of age or younger on the date of the first infusion of sebelipase alfa and thus eligible for the primary analysis of survival.</td>
</tr>
<tr>
<td>Main inclusion criteria</td>
<td>A subject must meet all of the following criteria to be eligible to participate in this study:</td>
</tr>
<tr>
<td>1.</td>
<td>Subject’s parent or legal guardian understands the full nature and purpose of the study, including possible risks and side effects, and provides written informed consent/permission prior to any study procedures being performed.</td>
</tr>
<tr>
<td>2.</td>
<td>Male or female child with a documented decreased LAL activity relative to the normal range of the lab performing the assay or documented result of molecular genetic testing (2 mutations) confirming a diagnosis of LAL Deficiency.</td>
</tr>
<tr>
<td>3.</td>
<td>Growth failure* with onset before 6 months of age, as defined by: weight decreasing across at least 2 of the 11 major centiles on a standard World Health Organization (WHO) weight-for-age (WFA) chart (1st, 3rd, 5th, 10th, 25th, 50th, 75th, 90th, 95th, 97th, 99th); OR body weight in kg below the 10th centile on a standard WHO WFA chart AND no weight gain for the 2 weeks prior to screening; OR loss of &gt;5% of birth weight in a child who is older than 2 weeks of age.</td>
</tr>
<tr>
<td>*NOTE regarding Inclusion Criterion # 3: In the unusual circumstance where a child has a rapidly progressive course of LAL Deficiency but does not meet growth failure criteria as defined above, the child may be included in the study if the Investigator has substantial clinical concerns based on evidence of the rapid disease progression requiring urgent medical intervention. Inclusion under these exceptional circumstances requires submission of a written summary of the infant’s medical status for review by the Sponsor and must be approved by a written confirmation from the Sponsor after consultation with the Safety Committee (SC). The subject must meet all other entry criteria as stated.</td>
<td></td>
</tr>
<tr>
<td>Main exclusion criteria</td>
<td>A subject who meets any of the following criteria will be ineligible to participate in this study:</td>
</tr>
<tr>
<td>1.</td>
<td>Clinically important concurrent disease or co-morbidities which, in the</td>
</tr>
<tr>
<td>Randomization strategy</td>
<td>This study is open label and is not randomized.</td>
</tr>
<tr>
<td>------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Location (e.g. regions)</td>
<td>Multi-center (approximately 10 primary study centers globally). Subjects who are medically stable, as determined by the Investigator, may transfer to a local medical center for long-term treatment, contingent upon the local medical center being appropriately qualified and securing the required regulatory and Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approvals. Scheduled study assessments may also be performed at a local medical center with access to the appropriate facilities and expertise.</td>
</tr>
<tr>
<td>Study duration for participants</td>
<td>The duration of each subject’s treatment in the study is expected to be at least 18 months, and subjects may continue to receive treatment in the study for up to 5 years.</td>
</tr>
<tr>
<td>Dosage, treatment regimen, route of administration and dose escalation strategy</td>
<td>Sebelipase alfa, a recombinant human lysosomal acid lipase (rhLAL) produced in transgenic Gallus, will be administered by IV infusion. All subjects will initiate treatment with sebelipase alfa at a dose of 0.35 mg/kg qw. After receiving 2 infusions at this starting dose, a subject will receive a dose increase to 1 mg/kg qw, contingent upon acceptable safety and tolerability of preceding infusions. A further dose escalation to 3 mg/kg qw may be considered for a subject who has received at least 4 infusions at a dose of 1 mg/kg qw and meets dose escalation criteria, as defined below, contingent upon acceptable safety and tolerability of preceding infusions. An independent Safety Committee will oversee safety in this study. The SC will review available safety data for each subject (1) following the first 2 infusions at a dose of 0.35 mg/kg qw to determine the acceptability of escalating the dose to 1 mg/kg qw and (2) following the first 2 infusions at a dose of 1 mg/kg qw to determine the acceptability of continuing treatment at this dose level. In addition, for subjects who exhibit either an early or late suboptimal clinical response at a dose of 1 mg/kg qw and are escalated to a dose of 3 mg/kg qw, the SC will review their safety data following the first 2 infusions at a dose of 3 mg/kg qw to determine the acceptability of continuing treatment at this dose level. The remainder of the safety data for all subjects will be reviewed during at least semi-annual periodic meetings of the SC and on an ad-hoc basis as needed in the event of unanticipated safety findings. If the SC does not approve a subject’s dose escalation from 0.35 mg/kg qw...</td>
</tr>
</tbody>
</table>
to 1 mg/kg qw, but deems it safe for the subject to continue treatment at the starting dose of 0.35 mg/kg qw, the subject may continue to receive this starting dose. Re-evaluation of dose escalation will be considered after subsequent SC review and discussion with Sponsor.

Subjects who do not tolerate a dose of 3 mg/kg qw or 1 mg/kg qw may receive a dose reduction to 1 mg/kg qw or 0.35 mg/kg qw, respectively, at the discretion of the Investigator in consultation with the Sponsor and, where appropriate, the SC. If a subject cannot tolerate a dose of 0.35 mg/kg qw, despite measures taken to manage any infusion-associated reactions (IARs), the subject will be discontinued from the study.

Subjects who are on treatment for at least 96 weeks and have been on a stable dose for at least 24 weeks, may transition to an every other week dosing schedule at the same dose they received on the weekly dosing schedule. If the subject meets dose escalation criteria while on the every other week dosing schedule they will either revert back to weekly dosing or if on 1 mg/kg qw can increase to 3 mg/kg qw dosing.

**Dose Escalation Criteria**

During the first 3 months of treatment, a subject may be considered to meet dose escalation criteria if he/she meets 2 or more of the following criteria after at least 4 infusions at a dose of 1 mg/kg qw:

- Failure to gain an average of 5 g/kg body weight per day AND the presence of either of the following:
  - weight-for-length (WFL) or weight-for-height (WFH) z-score < -2 based on WHO child growth standards; and/or
  - length-for-age (LFA) or height-for-age (HFA) z-score < -2 based on WHO child growth standards.
- Albumin < 3.5 g/dL;
- Alanine aminotransferase (ALT) > 2x upper limit of normal (ULN);
- Ongoing requirement for blood and/or platelet transfusion.

A subject may also be considered for dose escalation after at least 3 months of treatment if they meet the below criteria:

- Any other clinically important manifestation of LAL Deficiency on either clinical examination, laboratory assessment, or imaging which has either
  - not improved from baseline
  - improved and plateaued but has not normalized (Note: The definition of a plateauing of effect requires consideration of a minimal of 3 assessments.)
  - failed to normalize within 12 months of initiation of treatment

Manifestations include but are not restricted to the following: A decrease in weight for age defined as crossing ≥2 major centile lines on standard weight for age curves, serum transaminases, albumin <3.5 g/dL, hepatomegaly, splenomegaly or lymphadenopathy.

If the subject continues to meet the above defined dose escalation criteria after at least 4 infusions at a dose of 3 mg/kg qw, the Investigator may request of the Sponsor (in consultation with the SC) to increase the dose up to a maximum of 5 mg/kg qw. Requests will be reviewed on a case-by-case basis.
<table>
<thead>
<tr>
<th>Controls</th>
<th>There is no placebo or comparator in this study.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rescue treatment</td>
<td>No approved therapy has been shown to be effective for the treatment of LAL Deficiency. Hematopoietic stem cell transplantation has been used experimentally but has a high morbidity and mortality in this patient population.</td>
</tr>
</tbody>
</table>

**Efficacy**

The primary efficacy endpoint will be the proportion of subjects surviving to 12 months of age. Secondary survival endpoints will include proportion of subjects surviving to 18 and 24 months of age, and other timepoints, as data permit, and estimated median age at death. Survival rates and median age at death derived from this study will be compared to rates/times reported in the literature and information derived from a natural history study in a similar patient population (study LAL-1-NH01).

Other secondary efficacy endpoints will include (1) changes from baseline in percentiles and/or z-scores for WFA, WFL/WFH, and LFA/HFA and the corresponding growth status indicators of underweight, wasting, and stunting, as well as changes from baseline in z-scores for head circumference-for-age (HCFA) and mid-upper arm circumference-for-age (MUACFA); (2) changes from baseline in aspartate aminotransferase (AST) and ALT; (3) normalization of hemoglobin levels without requirement for blood transfusion; and (4) change from baseline in serum ferritin.

Exploratory efficacy endpoints will include changes and/or percent changes from baseline (or first available measurement if baseline data are unavailable) in (1) alkaline phosphatase, gamma glutamyltransferase (GGT), albumin, and direct (conjugated), indirect (unconjugated), and total bilirubin levels; (2) liver and spleen size/volume, as measured by ultrasound or magnetic resonance imaging (MRI); (3) hepatomegaly and/or splenomegaly (abdominal girth, liver size, and spleen size) by physical examination; (4) platelet levels; and (5) serum lipid levels (total cholesterol, triglycerides, high density lipoprotein [HDL], low density lipoprotein [LDL]). Dietary changes, including discontinuation of a low-fat/low-cholesterol diet and/or introduction of an unrestricted age-appropriate diet, will be evaluated on an exploratory basis. Development will also be assessed using Denver II developmental screening test.

The impact of anti-drug antibodies (ADAs) on efficacy endpoints will also be explored.

**Safety**

Safety endpoints will include the incidence of adverse events (AEs), serious adverse events (SAEs), and IARs; changes from baseline clinical laboratory tests; changes in vital signs (blood pressure, heart rate, respiratory rate, and temperature) during and post-infusion relative to pre-infusion values; physical examination findings; use of concomitant medications/therapies; and Characterization of ADAs, including ADA positivity rate, time to ADA positivity, median and peak ADA titer and time to peak ADA titer. The impact of ADAs on safety endpoints will also be explored. Further characterization of ADAs, including inhibitory and/or neutralizing ADAs and measurement of specific ADA subtypes (e.g., IgE), may be performed, if appropriate.

**Pharmacokinetics**

PK endpoints will include maximum observed serum concentration ($C_{max}$).
and apparent serum clearance (CL), as data permit. The impact of ADAs on sebelipase alfa PK will also be explored.

**Pharmacodynamics**

Exploratory disease-related biomarkers, which may be identified based on emerging information from the sebelipase alfa development program and scientific literature, will be analyzed by changes or percent changes from baseline.

**Sample size**

Approximately 8 subjects who meet the requirements for inclusion in the Primary Efficacy Analysis Set (see definition below) will be enrolled in this study. If 8 subjects are included in the Primary Efficacy Analysis set and 6 of these subjects survive to 12 months of age, the exact 95% confidence interval (CI) for 12-month survival would be (34.91%, 96.81%), with the lower limit exceeding the upper limit of the CI for a similar population of untreated patients in the natural history study LAL-1-NH01. In study LAL-1-NH01, of the 18 patients who had growth failure and had a known date of death, only one patient survived past 12 months of age (95% CI for 12-month survival = (0.14%, 27.29%)).

**Analysis Sets**

The Full Analysis Set (FAS) will include all subjects who received any amount of investigational medicinal product (IMP).

The Primary Efficacy Analysis Set will include subjects in the FAS who were no older than 8 months of age on the date of the first infusion of sebelipase alfa.

The PK Analysis Set will include all available sebelipase alfa serum concentration data for subjects who received at least one complete infusion of IMP in this study.

The Per Protocol Set (PPS) will include subjects in the Primary Efficacy Analysis Set who, in addition, receive at least 4 complete infusions of sebelipase alfa. This set will be used for sensitivity analyses of efficacy endpoints.

**General Considerations**

All data will be presented in listings, and summary tables and/or graphs will be provided, as appropriate. Unless otherwise noted, tabulations for efficacy endpoints will be presented for subjects in the Primary Efficacy Analysis Set and tabulations for other endpoints will be presented for subjects in the FAS. Descriptive summary statistics (n, mean, median, standard deviation, minimum and maximum) will be calculated for the continuous variables. Shift tables and/or frequencies and percentages will be produced for the categorical variables. As noted, 95% two-sided CIs will be calculated around the estimates based on the exact binomial distribution for binomial endpoints and the t-distribution for continuous endpoints.

Baseline will be defined as the last measurement prior to the first infusion of sebelipase alfa. (Note: For exploratory analyses, the first available measurement after initiation of treatment may be used as baseline if a pretreatment measurement is unavailable.) Survival rates will be based on the age of the subject. Other endpoints, unless otherwise noted, will be based on exposure (i.e., duration of time since the first infusion of sebelipase alfa).

A clinical study report (CSR) will be produced following analysis of the
primary endpoint (12-month survival) and will include all subject data available through 12 months of age or the date of death or early withdrawal. A final CSR will be generated after study completion.

Efficacy
Efficacy will be analyzed for the Primary Efficacy Analysis Set. If the PPS is not identical to the Primary Efficacy Analysis Set (i.e., if at least one patient in the Primary Efficacy Analysis Set is excluded from the PPS), efficacy analyses will be repeated for the PPS.

The primary efficacy endpoint is the proportion of subjects surviving to 12 months of age. It is not anticipated that any subjects will be lost to follow-up prior to 12 months of age, but a subject who is not confirmed to have survived to 12 months of age will not be considered to have met the primary endpoint. As a complementary analysis, Kaplan-Meier survival curves of survival since birth and survival since first dose of IMP will be presented. Survival at 18 and 24 months of age will be analyzed as described for the primary endpoint. Median age at death will also be calculated. A Kaplan-Meier estimate of median survival past first dose of IMP will be computed. Estimated survival rates and median age at death derived from this study will be compared to rates/times reported in the literature, and will be discussed in conjunction with information derived from a natural history study in a similar patient population (study LAL-1-NH01).

Anthropometric indicators of growth, standardized by age and gender in accordance with the methodology described by the WHO and using WHO growth charts, will be listed by study time point as observed values and as changes from baseline. Change from baseline in anthropometric data will be tabulated as continuous data. In addition, the percentages of subjects who meet criteria for underweight, stunting, and wasting will be tabulated for each timepoint. For anthropometric indicators of growth, age will be adjusted for prematurity if gestational age is <37 weeks and the subject is under 12 months of age. The adjustment will be made such that corrected age equals the chronological age minus the number of months premature.

Change and/or percent changes from baseline in AST, ALT, and serum ferritin will be tabulated for each evaluation timepoint. The proportion of subjects with abnormal hemoglobin at baseline who achieve transfusion-free hemoglobin normalization (TFHN) will be summarized, as will the proportion of subjects who maintain transfusion-free normal hemoglobin.

The Denver II total score and functional area scores will be derived from the questionnaire in accordance with the Technical Manual and compared to appropriate demographic norms. The total score and functional area scores will be summarized as continuous data and according to the classification as to whether the subject displays abnormal/normal development.

Shift tables will be used to tabulate dietary changes, including discontinuation of low-fat/low-cholesterol diet and/or introduction of an unrestricted age-appropriate diet. Observed values and changes and/or percent changes from baseline in other exploratory efficacy endpoints will be tabulated for each evaluation timepoint.

Safety
Safety will be analyzed for the FAS. All reported AEs will be listed from the date of written informed consent until
the end of participation in this study. Separate listings of SAEs and IARs will also be provided. The numbers and percentages of subjects experiencing any AE, any SAE, any IAR, any related AE, any related SAE, and discontinuations due to an AE will be tabulated. The frequency of treatment-emergent AEs, SAEs, and IARs by SOC and preferred term (coded using Medical Dictionary for Regulatory Activities [MedDRA®] version 14 or higher) will be tabulated. Frequencies will also be presented by the classifications of severity and causality. In addition, frequency of AEs, SAEs, and IARs will be presented for time periods spanning the entire course of treatment with sebelipase alfa: from the start of dosing with sebelipase alfa in this study to 3 months after the first dose, >3 to 6 months, >6 to 12 months, >12 to 18 months, >18 to 24 months and >24 months. As appropriate, additional listings, summary tables and graphics will be generated to evaluate IAR frequency and severity over time. A listing of subjects who withdraw from the study due to AEs will be presented, and the incidence of AEs leading to study discontinuation will be summarized.

Observed measurements and changes from baseline to each study timepoint in clinical laboratory data will be summarized. Clinically significant abnormal values will be listed. Frequencies of abnormal values relative to the laboratory normal range and clinically significant abnormal values will be tabulated for each study timepoint. Shift tables may also be provided. The percentage of subjects who become ADA positive, time to ADA positivity, median and peak immunoglobulin G (IgG) antibody titer, time to peak IgG antibody titer, and percentage of subjects who tolerize will be summarized; IgG antibody titer values will be tabulated at each study visit using summary statistics appropriate to the data.

Changes in vital signs from pre-infusion values to each time point during or post-infusion will be summarized. Abnormal findings/values for physical examinations, vital signs, and ECGs will also be listed. Concomitant medication/treatment data will be coded using the WHO-DRUG dictionary. All data will be listed, and the percentages of subjects receiving each concomitant medication/treatment will be tabulated.

**Pharmacokinetics**

Pharmacokinetics will be analyzed for the PK Analysis Set. \( C_{\text{max}} \) will be recorded from direct observation, and CL will be derived by non-compartmental analysis. PK parameters will be summarized by dose of sebelipase alfa, if applicable.

**Pharmacodynamics**

Pharmacodynamics will be analyzed for the FAS. Potential disease-related biomarkers will be listed, and observed values and changes and/or percent changes from baseline will be summarized by timepoint.

**Subgroup Analyses**

The impact of ADAs on safety, efficacy, PK, and PD endpoints will be explored descriptively. As subject numbers permit, other subgroup analyses of interest may be performed including, but are not limited to, age, gender, and race.

<p>| Measures to minimize pain and distress (only if specific for this study) | Local analgesic cream (e.g., eutectic mixture of local anesthetics [EMLA]) will be allowed at least 20-30 minutes (or according to applicable institutional guidelines) prior to IV placement or blood sampling. |</p>
<table>
<thead>
<tr>
<th>External safety review</th>
<th>Safety Committee</th>
</tr>
</thead>
</table>

Page 12 of 76

ALEXION PHARMACEUTICALS, INC. PROPRIETARY AND CONFIDENTIAL:
DO NOT COPY OR DISTRIBUTE WITHOUT PERMISSION
Table of Contents

PROTOCOL SYNOPSIS ........................................................................................................................ 4

LIST OF ABBREVIATIONS ..................................................................................................................... 16

1 INTRODUCTION .................................................................................................................................. 18

1.1 BACKGROUND ............................................................................................................................ 18
  1.1.1 Lysosomal Acid Lipase Deficiency ....................................................................................... 18
  1.1.2 LAL Deficiency Presenting in Infancy ................................................................................. 18
  1.1.3 Medical Plausibility of Enzyme Replacement Therapy for LAL Deficiency ...................... 19

1.2 INVESTIGATIONAL AGENT ...................................................................................................... 20

1.3 PRECLINICAL DATA ............................................................................................................... 20

1.4 CLINICAL DATA ...................................................................................................................... 22

1.5 DOSE RATIONALE AND RISK/BENEFITS ......................................................................... 22
  1.5.1 Dose Rationale .................................................................................................................... 22
  1.5.2 Risk/Benefit Assessment .................................................................................................... 24

2 STUDY OBJECTIVES ..................................................................................................................... 25

2.1 PRIMARY OBJECTIVE ........................................................................................................... 25

2.2 SECONDARY OBJECTIVES ................................................................................................ 25

2.3 EXPLORATORY OBJECTIVES ............................................................................................. 25

3 STUDY DESIGN .............................................................................................................................. 26

3.1 OVERVIEW OF STUDY DESIGN AND FLOW CHART ...................................................... 26
  3.1.1 Dose Escalation .................................................................................................................. 27

3.2 RATIONALE FOR STUDY DESIGN .................................................................................. 30
  3.2.1 Dose Selection .................................................................................................................. 30
  3.2.2 Outcome Variable Selection ............................................................................................ 30
  3.2.3 Study Duration ................................................................................................................. 32

4 STUDY POPULATION ..................................................................................................................... 33

4.1 TARGET POPULATION ......................................................................................................... 33

4.2 NUMBER OF SUBJECTS ....................................................................................................... 33

4.3 INCLUSION CRITERIA ........................................................................................................... 33

4.4 EXCLUSION CRITERIA ......................................................................................................... 34

4.5 CONCOMITANT MEDICATION AND TREATMENT ......................................................... 34

4.6 DISCONTINUATION OF SUBJECTS FROM TREATMENT OR ASSESSMENT ............... 34
  4.6.1 Premature Withdrawal from Study Participation .............................................................. 34
  4.6.2 Procedures for Discontinuation ....................................................................................... 35

4.7 SUBJECT REPLACEMENT POLICY .................................................................................. 35

4.8 SUBJECT RECRUITMENT AND SCREENING .................................................................... 36

5 SCHEDULE OF ASSESSMENTS AND STUDY PROCEDURES .................................................... 37

5.1 STUDY ASSESSMENTS ......................................................................................................... 37
  5.1.1 Informed Consent ............................................................................................................... 37
  5.1.2 Subject Eligibility .............................................................................................................. 37
  5.1.3 Medical History ................................................................................................................. 38
  5.1.4 Demographic Information ................................................................................................. 38
  5.1.5 Anthropometrics ............................................................................................................... 38
  5.1.6 Physical Examination ...................................................................................................... 38
  5.1.7 Abdominal Ultrasound ................................................................................................... 39
  5.1.8 Abdominal MRI ............................................................................................................... 39
  5.1.9 Vital Signs ....................................................................................................................... 39

Page 13 of 76

ALEXION PHARMACEUTICALS, INC. PROPRIETARY AND CONFIDENTIAL:
DO NOT COPY OR DISTRIBUTE WITHOUT PERMISSION
5.1.10 Electrocardiogram ................................................................. 40
5.1.11 Laboratory Assessments ......................................................... 40
5.1.12 Denver II Developmental Screening Test ............................... 41
5.1.13 Exploratory Biomarkers .......................................................... 42
5.1.14 Pharmacokinetic Assessments ................................................ 42
5.1.15 DNA Sample ........................................................................ 42
5.1.16 LAL Enzyme Activity ............................................................. 43
5.1.17 Liver Biopsy ........................................................................... 43

6 INVESTIGATIONAL MEDICINAL PRODUCT ........................................ 45

6.1 DESCRIPTION OF IMP ................................................................. 45
6.2 METHOD FOR ASSIGNING SUBJECTS TO TREATMENT GROUPS ........ 45
6.3 STORAGE AND DISPOSITION OF IMP ........................................ 45
   6.3.1 Receipt of IMP ...................................................................... 45
   6.3.2 Storage ................................................................................. 45
   6.3.3 Disposition ........................................................................... 46
6.4 PREPARATION AND ADMINISTRATION OF IMP ......................... 46
   6.4.1 Preparation of IMP ................................................................. 46
   6.4.2 Administration of IMP .......................................................... 46
6.5 INFUSION ASSOCIATED REACTIONS ............................................. 47
6.6 BLINDING OF IMP ........................................................................ 48
6.7 DESTRUCTION OF IMP ................................................................. 48

7 ASSESSMENT OF SAFETY .................................................................. 49

7.1 ADVERSE EVENTS AND LABORATORY ABNORMALITIES ................. 49
   7.1.1 Clinical Adverse Events .......................................................... 49
   7.1.2 Laboratory Test Abnormality ................................................... 51
7.2 HANDLING OF SAFETY PARAMETERS ........................................... 51
   7.2.1 Serious Adverse Events and Infusion-Associated Reactions(Immediately Reportable to the Sponsor) ......................... 51
   7.2.2 Adverse Event Reporting Period ............................................ 51
   7.2.3 Treatment and Follow-up of Adverse Events ......................... 51
   7.2.4 Follow-up of Abnormal Laboratory Test Values ...................... 51
   7.2.5 Pregnancy ............................................................................. 52
7.3 RECORDING OF ADVERSE EVENTS .............................................. 52
7.4 REPORTING OF SERIOUS ADVERSE EVENTS AND UNANTICIPATED PROBLEMS ......................................................... 52
   7.4.1 Investigator Reporting: Notifying the Study Sponsor ................. 53
   7.4.2 Investigator Reporting: Notifying the IRB/IEC .......................... 53
   7.4.3 Sponsor Reporting: Notifying Regulatory Authorities ............... 53
   7.4.4 Sponsor Reporting: Notifying Participating Investigators .......... 54
7.5 DOSE MODIFICATION AND STOPPING RULES ............................... 54
7.6 MEDICAL MONITORING ............................................................... 54
   7.6.1 Independent Safety Committee .............................................. 54

8 STATISTICAL PLAN .......................................................................... 56

8.1 GENERAL CONSIDERATIONS ....................................................... 56
8.2 DETERMINATION OF SAMPLE SIZE ........................................... 56
8.3 ANALYSIS SETS ........................................................................... 57
8.4 DEMOGRAPHICS AND BASELINE CHARACTERISTICS ............... 57
8.5 SUBJECT ACCOUNTABILITY .......................................................... 57
8.6 STUDY TREATMENT USAGE AND COMPLIANCE ......................... 58
8.7 EFFICACY ANALYSIS ................................................................. 58
8.8 SAFETY ANALYSIS ....................................................................... 59
8.8.1 Adverse Events ..................................................................................................................... 59
8.8.2 Clinical Laboratory Tests ....................................................................................................... 60
8.8.3 Other Safety Data .................................................................................................................. 60
8.9 Pharmacokinetics .................................................................................................................... 60
8.10 Pharmacodynamic Analysis ..................................................................................................... 60
8.11 Other Statistical Issues ........................................................................................................... 60
8.11.1 Significance Levels ........................................................................................................... 60
8.12 Subgroup Analyses ................................................................................................................... 60
8.13 Missing or Invalid Data ............................................................................................................ 60
8.14 Interim Analysis ....................................................................................................................... 60
9 DATA HANDLING AND RECORD KEEPING ................................................................................. 61
9.1 Confidentiality .......................................................................................................................... 61
9.2 Source Documents .................................................................................................................... 61
9.3 Case Report Forms ................................................................................................................... 61
9.4 Records Retention ..................................................................................................................... 61
10 STUDY MONITORING, AUDITING, AND INSPECTING .......................................................... 62
10.1 Study Monitoring Plan ............................................................................................................ 62
10.2 Auditing and Inspecting ......................................................................................................... 62
11 ETHICAL CONSIDERATIONS ..................................................................................................... 63
12 CLINICAL STUDY REPORT AND PUBLICATION PLAN ...................................................... 64
13 REFERENCES ................................................................................................................................ 65
14 APPENDICES ................................................................................................................................ 68

APPENDIX A: SCHEDULE OF ASSESSMENTS TABLE 1 -- SCREENING THROUGH WEEK 24 .............. 69
APPENDIX B: DIAGNOSIS AND RECOMMENDATIONS FOR MANAGEMENT OF INFUSION ASSOCIATED REACTIONS .................................................................................................................. 74
APPENDIX C: DOSE MODIFICATION AND STOPPING RULES FOR LAL-CL03 STUDY ...................... 76

LIST OF TABLES
TABLE 1 MEAN BLOOD VOLUME, BY AGE ......................................................................................... 37
TABLE 2 CLINICAL LABORATORY TESTS, BY TIER .......................................................................... 40
TABLE 3 ASSESSMENT OF CAUSALITY ............................................................................................. 50
List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADA</td>
<td>Anti-drug Antibody</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>ALT/SGPT</td>
<td>Alanine Aminotransferase</td>
</tr>
<tr>
<td>aPTT</td>
<td>Activated Partial Thromboplastin Time</td>
</tr>
<tr>
<td>AST/SGOT</td>
<td>Aspartate Aminotransferase</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence Interval</td>
</tr>
<tr>
<td>CL</td>
<td>Clearance</td>
</tr>
<tr>
<td>C_{max}</td>
<td>Maximum Observed Plasma Concentration</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>DBS</td>
<td>Dried Blood Spot</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>eCRF</td>
<td>Electronic Case Report Form</td>
</tr>
<tr>
<td>EMA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>EMLA</td>
<td>Eutectic Mixture of Local Anesthetics</td>
</tr>
<tr>
<td>ERT</td>
<td>Enzyme Replacement Therapy</td>
</tr>
<tr>
<td>FAS</td>
<td>Full Analysis Set</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>GlcNAc</td>
<td>N-acetylglucosamine</td>
</tr>
<tr>
<td>GGT</td>
<td>Gamma Glutamyltransferase</td>
</tr>
<tr>
<td>HDL</td>
<td>High Density Lipoprotein</td>
</tr>
<tr>
<td>HFA</td>
<td>Height-for-Age</td>
</tr>
<tr>
<td>HCFA</td>
<td>Head circumference-for-age</td>
</tr>
<tr>
<td>IAR</td>
<td>Infusion Associated Reaction</td>
</tr>
<tr>
<td>IB</td>
<td>Investigator Brochure</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>IEC</td>
<td>Independent Ethics Committee</td>
</tr>
<tr>
<td>IM</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>IMP</td>
<td>Investigational Medicinal Product</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>LAL</td>
<td>Lysosomal Acid Lipase</td>
</tr>
<tr>
<td>LDL</td>
<td>Low Density Lipoprotein</td>
</tr>
<tr>
<td>LFA</td>
<td>Length-for-Age</td>
</tr>
<tr>
<td>LLN</td>
<td>Lower Limit of Normal</td>
</tr>
<tr>
<td>LSD</td>
<td>Lysosomal Storage Disorder</td>
</tr>
<tr>
<td>M6P</td>
<td>Mannose-6-Phosphate</td>
</tr>
<tr>
<td>MCV</td>
<td>Mean Corpuscular Volume</td>
</tr>
</tbody>
</table>
MCH(C)  Mean Corpuscular Hemoglobin (Concentration)
MedDRA  Medical Dictionary for Regulatory Activities
MHRA  Medicines and Healthcare Products Regulatory Agency
MMR  Macrophage Mannose Receptor
MRI  Magnetic Resonance Imaging
mRNA  Messenger Ribonucleic Acid
MUACFA  Mid-upper Arm Circumference-for-Age
PBMC  Peripheral Blood Mononuclear Cells
PT (INR)  Prothrombin Time (International Normalized Ratio)
PD  Pharmacodynamics
PK  Pharmacokinetics
PPS  Per Protocol Set
rhLAL  Recombinant Human Lysosomal Acid Lipase
SAE  Serious Adverse Event
SC  Safety Committee
SOC  System Organ Class
TFHN  Transfusion-Free Hemoglobin Normalization
WFA  Weight-for-Age
WFH  Weight-for-Height
WFL  Weight-for-Length
1 Introduction
This document is a protocol for a human research study. This study is to be conducted according to United States and international standards of Good Clinical Practice (GCP) (FDA Title 21 part 312 and International Conference on Harmonisation [ICH] guidelines), applicable government regulations and Institutional research policies and procedures.

1.1 Background

1.1.1 Lysosomal Acid Lipase Deficiency
Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lipid storage disorder that is caused by a marked decrease or almost complete absence of the lysosomal enzyme, LAL.

The marked reduction or almost complete absence of LAL in patients with LAL Deficiency leads to the accumulation of lipids, predominately cholesteryl esters and triglycerides, in various tissues and cell types, particularly the liver leading to hepatomegaly, liver dysfunction, and hepatic failure, and in the small intestinal macrophages leading to profound malabsorption. LAL Deficiency presenting in infancy is characterized by profound malabsorption, growth failure, and hepatic failure and is usually fatal within the 6 months of life. In children and adults with LAL Deficiency, liver involvement and type II hyperlipidemia dominate the clinical picture. All presentations of LAL Deficiency are due to mutations in the LIPA gene located on chromosome 10q23.2-q23.3. In LAL Deficiency presenting in children and adults, many cases are associated with a common mutated allele resulting in some residual enzyme activity, whereas in LAL Deficiency presenting in infants there are a variety of private mutations with complete loss of enzyme function (Assmann, 2001, The Metabolic and Molecular Basis of Inherited Disease). It has been hypothesized that there may be a correlation between enzyme activity and the severity of the disease.

1.1.2 LAL Deficiency Presenting in Infancy
LAL Deficiency presenting in infants, historically called Wolman disease or LAL Deficiency/Wolman phenotype is a very rare form of LAL Deficiency that is usually fatal within the first 6 months of life (Assmann, 2001, The Metabolic and Molecular Basis of Inherited Disease). This form of the disease, named after the physician who first described it (Abramov, 1956, AMA J Dis Child), is the most rapidly progressive presentation of LAL Deficiency with growth failure and severe hepatic disease, as evidenced by liver enlargement, elevation of transaminases, hyperbilirubinemia, coagulopathy and hypoalbuminemia, as the predominant clinical features and key contributors to the early mortality (Anderson, 1999, Mol Genet Metab; Mayatepek, 1999, J Inherit Metab Dis). Fibrosis and cirrhosis develop rapidly and have been described in affected infants within the first 6 months of life (Marshall, 1969, Arch Dis Child; Konno, 1966, Tohoku J Exp Med; Crocker, 1965, Pediatrics).

Diagnosis of LAL Deficiency is established through both physical findings and laboratory analyses. Infants are typically hospitalized within the first 2 months of life due to diarrhea, persistent vomiting, feeding difficulty and growth failure (Wolman, 1995, Clin Pediatr). Physical
findings include abdominal distention with hepatomegaly and splenomegaly. Radiographic examination often reveals calcification of the adrenal glands. Laboratory evaluations typically reveal elevated levels of serum transaminases and absent or markedly reduced LAL enzyme activity (Assmann, 2001, The Metabolic and Molecular Basis of Inherited Disease; Mayatepek, 1999, J Inherited Metab Dis; Surve, 2005, Indian J Pediatr).

At present, there are no safe or effective therapies for the treatment of patients with LAL Deficiency. A variety of supportive therapies are used in an attempt to mitigate some of the effects of this rapidly fatal disease. Antibiotics may be prescribed to address pyrexia or documented infections. In an attempt to mitigate the complications due to lipid accumulation within the target cells and vital organs, dietary restriction of either breast milk or formulas containing triglycerides and cholesteryl esters and the use of a fatty ester free diet is recommended (Wolman, 1995, Clin Pediatr). Although some stabilization of the clinical condition has been described with nutritional support, these interventions do not substantially modify the outcome in affected patients (LAL-1-NH01; Hoeg, 1984, Am J Hum Genet; Meyers, 1985, Nutr Res).

Outcomes with hematopoietic stem cell transplantation in affected infants have recently been reviewed in the literature, and while there are reports that 3 transplanted patients have survived beyond 3 years, the majority of transplant attempts resulted in early death due to liver failure from progressive disease, or sinusoidal obstruction syndrome (veno-occlusive disease) or other transplant-related complications (Gramatges, 2009, Bone Marrow Transplant; Krivit 1992, Bone Marrow Transplant; Tolar, 2009, Bone Marrow Transplant; Yanir, 2013, Mol Gen Metab). The toxicity of conditioning regimens and time required for engraftment create substantial risks in the setting of such a rapidly progressive disease as LAL Deficiency presenting in infants.

1.1.3 Medical Plausibility of Enzyme Replacement Therapy for LAL Deficiency

LAL Deficiency resembles other lysosomal storage disorders (LSDs) with the accumulation of substrate in a number of tissues and cell types. The successful treatment of Gaucher disease with placental glucocerebrosidase in the 1990s and, with the follow-on enzyme produced by recombinant deoxyribonucleic acid (DNA) technology, established the medical value and long-term safety of enzyme replacement therapy (ERT) for LSDs (Barton, 1990, Proc Natl Acad Sci; Barton, 1991, N Engl J Med). The scientific concepts established by these initial studies have now been extended to a broader range of disorders, including Pompe disease (Kishnani, 2007, Neurology; van der Ploeg, 2010, N Engl J Med), Fabry disease (Wilcox, 2004, Am J Hum Genet), Mucopolysaccharidosis I (Wraith, 2004, J Pediatr), and Mucopolysaccharidosis II (Muenzer, 2007, Mol Genet Metab) and there is now extensive clinical experience of long-term ERT in patients with LSDs.

In LAL Deficiency, substrate accumulation is most marked in cells of the reticuloendothelial system, including Kupffer cells in the liver, histiocytes in the spleen and macrophages in the lamina propria of the small intestine. Reticuloendothelial cells express the macrophage mannose/N-acetylglucosamine receptor (also known as macrophage mannose receptor or
MMR, CD206), which mediates binding, cell uptake and lysosomal internalization of proteins with N-acetylglucosamine (GlcNAc) or mannose terminated N-glycans, and provides a pathway for the potential correction of the enzyme deficiency in these key cell types (Stahl, 1978, Proc Natl Acad Sci). This knowledge and the precedent established for other LSDs provides plausibility that ERT with sebelipase alfa, which has the appropriate glycan characteristics for targeting macrophages and other key cells, will benefit patients with LAL Deficiency.

Biological activity of sebelipase alfa in patients with LAL Deficiency has been demonstrated in clinical study LAL-CL01 and LAL-CL04, including decreases in transaminases and evidence of early lipid mobilization and correction of dyslipidemia with longer term dosing. This information and the encouraging initial response to sebelipase alfa in LAL-CL03, including improvements in weight gain, decrease in hepatic and splenic size, resolution of vomiting and diarrhea, and improvement in biochemical markers, provides the first human evidence in support of the potential for ERT for this disease).

1.2 Investigational Agent

Sebelipase alfa is a recombinant human lysosomal acid lipase (rhLAL) with the same amino acid sequence as the native enzyme. Sebelipase alfa is a highly purified recombinant form of the naturally occurring human lysosomal acid lipase enzyme responsible for the metabolism and degradation of cholesteryl esters and triglycerides that are delivered to lysosomes by a variety of routes including low density lipoprotein (LDL) receptor mediated endocytosis. Sebelipase alfa is a glycoprotein with a molecular weight of approximately 55 kD with 5 N-linked glycosylation sites.

Sebelipase alfa is produced by recombinant DNA technology in egg white using a transgenic Gallus expression system and contains predominantly GlcNAc and mannose terminated N-linked glycan structures, some of which contain mannose-6-phosphate (M6P). GlcNAc and mannose terminated glycans are specifically recognized and internalized via the MMR present on the surface of macrophages. These cells are one of the most important cell types that accumulate cholesteryl esters and triglycerides in patients with LAL Deficiency. In addition, the presence of M6P allows delivery to cells that display the widely expressed M6P receptor.

1.3 Preclinical Data

In in vitro studies, sebelipase alfa demonstrated uptake and localization to lysosomes, and produced a dose-dependent correction of LAL activity in human fibroblasts deficient in this enzyme.

In homozygous LAL-deficient rats, a nonclinical disease model of LAL Deficiency, intravenous (IV) administration of sebelipase alfa restored enzyme activity in the liver and other key target tissues, and was associated with a marked reduction in substrate accumulation (cholesteryl esters and triglycerides) in the liver, spleen, gut, and lymph nodes relative to placebo-treated animals. Homozygous LAL-deficient rats demonstrate liver and spleen abnormalities, which resemble the abnormalities seen in patients with LAL Deficiency including accumulation of cholesteryl esters and triglycerides, hepatosplenomegaly, transaminase elevation, Kupffer cell
expansion with disruption of normal liver architecture and liver fibrosis (Leavitt, 2011, J Hepatol). In addition, the LAL-deficient rats show other abnormalities that are prominent in rapidly progressing LAL Deficiency, including gastrointestinal involvement with abnormal lipid accumulation in macrophages in the lamina propria of the small intestine, markedly impaired weight gain, and early mortality (Leavitt, 2011, J Ped Gastroenterol Nutr; Sponsor data on file). Once weekly (qw) and every other week (qow) administration of sebelipase alfa by IV injection administered over a 4-week period led to a statistically significant improvement (p<0.05) in weight gain and organ size compared to placebo-treated LAL-deficient rats. Of note, the improvements in weight gain were statistically significant within 2 weeks of initiation of the first dose. Liver abnormalities were all markedly improved within 4 weeks of treatment initiation. In a subsequent study, sebelipase alfa was administered to LAL-deficient rats qw at a dose of 3 mg/kg (given by bolus tail vein injection) for 19 weeks, beginning at 8 weeks of age, to investigate the effectiveness of sebelipase alfa in the presence of more advanced disease and to determine whether restoration of growth and correction of other disease-related abnormalities with sebelipase alfa treatment was associated with extended survival. In this study, sebelipase alfa treatment resulted in substantial improvements in the phenotypic abnormalities seen in this disease model. Sebelipase alfa-treated LAL-deficient rats gained more weight than vehicle-treated animals, and survived without exception to the scheduled sacrifice time (27 weeks of age); in a separate study, untreated animals did not survive beyond 14 weeks of age. The growth rate of the sebelipase alfa-treated LAL-deficient rats was sustained through study termination in a manner comparable to wildtype rats. Favorable responses were observed with regard to organomegaly, with reductions in the size of all affected organs examined, and a concomitant reduction in hepatic levels of LAL substrates, consistent with the expected mechanism of action of sebelipase alfa. The reduction in hepatomegaly was also accompanied by a normalization of serum transaminases. Histologically, the appearance of the liver in the sebelipase alfa-treated LAL-deficient rats resembled that of the wildtype rat. These positive disease-modifying effects of sebelipase alfa were comparable to the effects observed following short-term (4 weeks) administration. Additional discussions of the dose response of the effects seen in the nonclinical model are included in Section 1.5.1.

There were no meaningful toxicological findings in 4-week repeat dose toxicology studies in the Sprague-Dawley rat and Cynomolgus monkey administered IV infusions of sebelipase alfa at doses up to 50 mg/kg qw. In a 6-month repeated dose toxicity study in juvenile Cynomolgus monkeys administered qw IV infusions of sebelipase alfa at doses of 3 mg/kg, 10 mg/kg or 30 mg/kg (5 males and 5 females per dose group), or placebo infusions (5 males, 5 females), sebelipase alfa was well tolerated up to the highest dose level of 30 mg/kg. There were no sebelipase alfa related changes in any of the study parameters, although there was an apparent infusion reaction observed in one animal on Day 1 of dosing following administration of sebelipase alfa at a dose of 10 mg/kg. With diphenhydramine pretreatment, no additional reactions were observed during the subsequent 25 infusions in this animal. No infusion reactions were observed in a total of 754 infusions administered to the other 29 animals in this study. These results support the long-term dosing with sebelipase alfa.
Pharmacokinetic (PK) studies in Sprague-Dawley rats administered IV bolus injections of sebelipase alfa at doses of 1 mg/kg and 5 mg/kg demonstrate that sebelipase alfa is rapidly cleared from the circulation and uptake appears to be saturable.

1.4 Clinical Data

The clinical development program is investigating the safety and tolerability of sebelipase alfa and its clinically meaningful effects on the medical complications of LAL Deficiency. LAL-CL01, a Phase 1/2 dose-finding study in adults with LAL Deficiency, has completed. An extension study, LAL-CL04, is ongoing in subjects who completed LAL-CL01. LAL-CL03 is an ongoing Phase 2/3 study to evaluate the safety, tolerability, efficacy, PK and pharmacodynamics (PD) of sebelipase alfa in pediatric subjects with LAL Deficiency who developed growth failure or other clinical evidence of rapidly progressive LAL Deficiency before 6 months of age. LAL-CL02 is an ongoing Phase 2 study to evaluate efficacy, safety, and PK of sebelipase alfa or placebo in pediatric and adult subjects with LAL Deficiency. LAL-CL06 is a Phase 2 study in a broad population of subjects ≥ 8 months with LAL Deficiency who may not have been eligible for other studies. LAL-CL08 is a Phase 2 study in infant subjects with rapidly progressive LAL Deficiency. Please refer to the IB for further information on the clinical experience with sebelipase alfa.

1.5 Dose Rationale and Risk/Benefits

1.5.1 Dose Rationale

In this study, sebelipase alfa will be administered at a starting dose of 0.35 mg/kg qw and all subjects will receive a dose increase to 1 mg/kg (contingent on safety), with an option for a further dose increase to 3 mg/kg qw. These doses of sebelipase alfa were selected based on the following:

- As discussed in Section 1.4, clinical data are available from a completed study in patients with LAL Deficiency (LAL-CL01) administered qw infusions of sebelipase alfa at doses of 0.35 mg/kg, 1 mg/kg, or 3 mg/kg as well as 1 mg/kg, or 3 mg/kg qow (LAL-CL04). These data show:
  - All 3 dose levels of sebelipase alfa were well tolerated.
  - Sebelipase alfa therapy produced rapid and comparable reductions in serum transaminases at all 3 dose levels.
  - Increases in serum lipids were seen at all 3 dose levels within 4 weeks of treatment initiation, consistent with the known mechanism of action of sebelipase alfa. These effects were more marked with the 3 mg/kg qw dose and may therefore be dose related. Compared to a dose of 3 mg/kg qw, doses of 0.35 and 1 mg/kg qw may have less marked short-term effects on serum lipids, but a potentially comparable clinical benefit.
- Maintenance of clinical response (reduction in ALT and AST and improvement of lipid levels) was observed in adult subjects treated with qow dosing in LAL-CL04.

- There is an adequate safety margin for sebelipase alfa based on nonclinical toxicology studies. Refer to the IB for further information.

  - There were no meaningful toxicological findings in 4-week repeated dose toxicology studies in the Sprague-Dawley rat and Cynomolgus monkey at doses up to 50 mg/kg. Based on the human equivalent doses in rats (8.1 mg/kg) and monkeys (16.1 mg/kg), this represents an approximately 23.0- to 46.1-fold safety margin relative to the planned starting dose of 0.35 mg/kg in the current study.

  - Sebelipase alfa was well tolerated in a 6-month repeated dose toxicity study in Cynomolgus monkeys given qw IV infusions at doses up to 30 mg/kg. Based on the human equivalent dose (9.7 mg/kg), this provides an approximately 27.7-fold safety margin relative to the planned starting dose of 0.35 mg/kg in the current study. The absence of any sebelipase alfa related changes in study parameters supports the long-term dosing with sebelipase alfa.

- As expected, based on the number and composition of glycan structures, PK studies in Sprague-Dawley rats administered IV bolus injections of sebelipase alfa at doses of 1 mg/kg and 5 mg/kg demonstrate that sebelipase alfa is rapidly cleared from the circulation and uptake appears to be saturable. Consistent with these findings, sebelipase alfa has a short plasma half-life in adult patients with late onset LAL Deficiency. Clinical PK data for sebelipase alfa are not yet available for children and adolescents, but plasma half-life is expected to be short in these patients.

- A dose of 0.35 mg/kg dose qw was established as the minimally effective dose in a rat model of LAL Deficiency.

- In general for LSDs, the enzymatic activities and mechanisms for lysosomal targeting are conserved across species. Toxicological studies of this class of therapy consistently demonstrate low systemic toxicity (Andrews and O'Callaghan, 2008).

- The Investigational Medicinal Product (IMP) has an amino acid sequence identical to the Genbank reference sequence for human LAL with no engineering of enhancements in biological activity.

For ERTs, plasma PK data have limited utility for dose selection and escalation, as the proteins have a short plasma half-life and the main biological activity is in the target tissue.

Given the extreme rarity and immediate life-threatening nature of growth failure due to LAL Deficiency, this study will allow within-subject dose escalation from the initial starting dose, as the pre-clinical model demonstrated dose dependent pharmacological effects. The proposed dose increment permitted in this study will be 3-fold, which will allow assessment of safety, tolerability and efficacy in children across a range of doses on a mg/kg basis. In the preclinical rat model, it was established that the pharmacodynamic (PD) effects of 3 mg/kg qw and 5 mg/kg qw are comparable. Based on this information, it is not anticipated that exploration of doses...
greater than 3 mg/kg qw in subjects with LAL Deficiency will be required unless there is evidence of a loss of efficacy due to the potential development of neutralizing antibodies.

1.5.2 Risk/Benefit Assessment

LAL Deficiency is a very rare disease with no safe or effective therapies. LAL Deficiency presenting in infants results in significant morbidity and death typically within 6 months of age (Assmann, 2001, *The Metabolic and Molecular Basis of Inherited Disease*).

No significant toxicities were identified in pre-clinical pharmacology and toxicology studies at doses equivalent to and substantially greater than the planned doses for the current study (see Section 1.3 for details).

Clinical experience with sebelipase alfa in adult patients with LAL Deficiency treated in study LAL-CL01 and LAL-CL04 indicates that sebelipase alfa is well tolerated at doses ranging from 0.35 mg/kg qw to 3 mg/kg qw and produces rapid improvements in serum transaminases and other evidence of biological activity. Sebelipase alfa has also demonstrated an acceptable safety profile and positive treatment effects in infants receiving doses up to 3 mg/kg qw on an expanded access basis and in the current study. See Section 1.4 and the IB for further details on the clinical experience with sebelipase alfa. Thus, there is a reasonable basis to conclude that sebelipase alfa therapy in this study will be well tolerated and associated with beneficial effects on disease activity.

In addition to clinical experience with sebelipase alfa, extensive human experience exists for ERTs in the treatment of other LSDs including Gaucher, Pompe, and Fabry disease. The main unfavorable effects associated with administration of approved ERTs (including but not limited to Cerezyme®, VPRIV®, Myozyme®/Lumizyme®, Fabrazyme®) are IARs, which typically occur during or within several hours following completion of the infusion and are usually mild and can be managed by changes in infusion rate and/or the administration of antipyretics and antihistamines. Severe infusion reactions including anaphylaxis, and SAEs related to ERT administration occur rarely and can require intensive medical intervention. Given the propensity for infusion reactions with ERT administration, measures have been incorporated in this protocol to minimize risk and monitor subject safety.

Anti-drug antibodies (ADAs) have been reported with approved ERTs and these may be associated with altered response to treatment and/or increased risk of infusion reactions.

Given the relatively low level of subject risk relative to the terminal nature of untreated LAL Deficiency presenting in infancy, it is concluded that the risks to subjects in this study are reasonable in relation to the anticipated benefits and/or knowledge that can be expected from the results.
2 Study Objectives

2.1 Primary Objective
The primary objective of the study is to evaluate the effect of sebelipase alfa therapy on survival at 12 months of age in children with growth failure due to LAL Deficiency.

2.2 Secondary Objectives
The secondary objectives are:

- To evaluate the safety and tolerability of sebelipase alfa in children with growth failure due to LAL Deficiency;
- To evaluate the effect of sebelipase alfa therapy on survival beyond 12 months of age in children with growth failure due to LAL Deficiency;
- To evaluate the effects of sebelipase alfa on growth parameters in children with growth failure due to LAL Deficiency;
- To evaluate the effects of sebelipase alfa on hepatomegaly, splenomegaly, and liver function in children with growth failure due to LAL Deficiency;
- To determine the effects of sebelipase alfa on hematological parameters in children with growth failure due to LAL Deficiency;
- To characterize the PK of sebelipase alfa delivered by IV infusion.

2.3 Exploratory Objectives
The exploratory objectives are:

- To determine the effects of sebelipase alfa on lipid parameters in children with growth failure due to LAL Deficiency;
- To assess the effects of sebelipase alfa on achievement of developmental milestones in children with growth failure due to LAL Deficiency;
- To assess the effects of sebelipase alfa on the ability of children with LAL Deficiency to tolerate an unrestricted diet;
- To evaluate potential disease-related biomarkers.
3 Study Design

3.1 Overview of Study Design and Flow Chart

This is an open-label, repeat-dose, dose escalation study of sebelipase alfa in children with growth failure due to LAL Deficiency. Eligible subjects will receive IV infusions of sebelipase alfa for up to 5 years, as described below. All subjects will be evaluated for safety, tolerability, and efficacy. Where feasible, given blood volume thresholds based on subject weight, blood samples will also be collected for analyses of the PK and PD of sebelipase alfa and for an exploratory analysis of potential disease-related biomarkers in this patient population.

All subjects will initiate treatment with sebelipase alfa at a dose of 0.35 mg/kg qw. After receiving 2 infusions at this starting dose, a subject will receive a dose increase to 1 mg/kg qw, contingent upon acceptable safety and tolerability of preceding infusions. A further dose escalation to 3 mg/kg qw may be considered for a subject who has received at least 4 infusions at a dose of 1 mg/kg qw, and meets the criteria for dose escalation defined in Section 3.1.1, contingent upon acceptable safety and tolerability of preceding infusions.

An independent safety committee will oversee safety in this study. The SC will review available safety data for each subject (1) following the first 2 infusions at a dose of 0.35 mg/kg qw to determine the acceptability of escalating the dose to 1 mg/kg qw and (2) following the first 2 infusions at a dose of 1 mg/kg qw to determine the acceptability of continuing treatment at this dose level. In addition, for subjects who are escalated to a dose of 3 mg/kg qw, the SC will review their safety data following the first 2 infusions at a dose of 3 mg/kg qw to determine the acceptability of continuing treatment at this dose level. The remainder of the safety data for all subjects will be reviewed during at least biannual periodic meetings of the SC and on an ad-hoc basis as needed in the event of unanticipated safety findings.

If the SC does not approve a subject’s dose escalation from 0.35 mg/kg qw to 1 mg/kg qw, but deems it safe for the subject to continue treatment at the starting dose of 0.35 mg/kg qw, the subject may continue to receive this starting dose. Re-evaluation of dose escalation will be considered after subsequent SC review and discussion with Sponsor.

Subjects who do not tolerate a dose of 3 mg/kg qw or 1 mg/kg qw may receive a dose reduction to 1 mg/kg qw or 0.35 mg/kg qw, respectively, at the discretion of the Investigator in consultation with the Sponsor and, where appropriate, the SC. If a subject cannot tolerate a dose of 0.35 mg/kg qw, despite measures taken to manage any IARs, the subject will be discontinued from the study.

Subjects who are on treatment for at least 96 weeks and have been on a stable dose for at least 24 weeks, may transition to an every other week dosing schedule at the same dose they received on the weekly dosing schedule. If the subject meets the criteria for dose escalation while on the every other week dosing schedule they will either revert back to weekly dosing or if on 1 mg/kg qow can increase to 3 mg/kg qow dosing.

Given the severity and life threatening nature of rapidly progressive LAL Deficiency, it is likely that these subjects will be hospitalized during the first several weeks on study. For the subjects...
who are stable enough to be treated on an outpatient basis, safety follow-up assessments for AEs will be conducted by telephone 24 hours following the first 2 infusions of 0.35 mg/kg qw, 1 mg/kg qw, as well as 3 mg/kg qw, if needed. Additional details about the SC review process can be found in Section 7.6. Refer to Appendix A for the full Schedule of Assessments.

Subjects who appear to have an acute illness (e.g., upper respiratory infection or febrile illness) should have their scheduled infusions postponed by up to 2 days (5 days if subject is on a qw infusion schedule) to allow for resolution. If the illness persists for longer than 2 days (5 days if subject is on a qw infusion schedule), the infusion schedule should reset to the next scheduled infusion after the subject’s recovery. The Investigator may conduct an unscheduled visit at any time during the study at his/her discretion. Assessments performed at this visit should be symptom directed. Safety laboratory testing may be performed if the Investigator considers it necessary. Repeat laboratory testing may be needed based on results from the unscheduled laboratory testing. If the subject is discontinued from study treatment at a scheduled visit or at an unscheduled visit, the subject should return no earlier than 7 days after the last dose of IMP for an End of Study assessment.

3.1.1 Dose Escalation

The Investigator, in consultation with the Sponsor and Safety Committee (SC), may consider increasing a subject’s dose to 3 mg/kg qw by monitoring subjects for evidence of the below specified criteria that may reflect a need for a dose increase. These considerations should include evaluation of other potential causes of any clinical manifestations that are thought negatively impact these criteria.

. Other causes could include:

- missed study infusions,
- onset of acute cholecystitis or initiation of a potentially hepatotoxic concomitant medication in a subject with elevated ALT,
- concomitant illness in a subject with reduced weight gain such as an upper respiratory tract infections or other childhood viral infection.

3.1.1.1 Dose escalation criteria during first 3 months of treatment

During this period, a subject may be considered for dose escalation if he/she meets 2 or more of the following criteria after at least 4 infusions at a dose of 1 mg/kg qw:

- Failure to gain an average of 5 g/kg body weight per day AND the presence of either of the following:
  - weight-for-length (WFL) or weight-for-height (WFH) z-score <-2 based on World Health Organization (WHO) child growth standards; and/or
  - length-for-age (LFA) or height-for-age (HFA) z-score <-2 based on WHO child growth standards.
- Albumin <3.5 g/dL;
- Alanine aminotransferase (ALT) >2x upper limit of normal (ULN);
- Ongoing requirement for blood and/or platelet transfusion.

3.1.1.2 **Dose escalation after at least 3 months of treatment**
- Any other clinically important manifestation of LAL Deficiency on either clinical examination, laboratory assessment, or imaging which has either
  - not improved from baseline
  - improved and plateaued but has not normalized
    (Note: The definition of a plateauing of effect requires consideration of a minimal of 3 assessments.)
  - failed to normalize within 12 months of initiation of treatment,

Manifestations include but are not restricted to the following: A decrease in weight for age defined as crossing ≥2 major centile lines on standard weight for age curves, serum transaminases, albumin <3.5 g/dL, hepatomegaly, splenomegaly or lymphadenopathy.

If the subject continues to have criteria for dose escalation after at least 4 infusions at a dose of 3 mg/kg qw, the Investigator, may request of the Sponsor (in consultation with the SC) to increase the dose up to a maximum of 5 mg/kg qw on a case by case basis.

Prior to any dose change, serum lipid, serum liver, hematology, chemistry, ferritin and hs-CRP shall be obtained. Serum lipid and serum liver assessments should be taken 4, 8, and 12 weeks following any study drug or lipid drug dose change.
Figure 1    Initial Dose Escalation- Safety Committee Review Flow

Note: All dose increases are contingent upon acceptable safety and tolerability during preceding infusions. Note: Dose reductions are permitted in the event of poor tolerability. See Section 3.1 for details. *Subjects will receive a dose of 1 mg/kg qw through 96 weeks, except where a subject's dose after at least 4 infusions of 1 mg/kg qw meets dose escalation criteria as defined in Section 3.1.1) and a dose increase to 3 mg/kg qw is approved. Subjects may transition to an every other week dosing schedule after 96 weeks if on a stable dose for at least 24 weeks.
3.2 Rationale for Study Design

3.2.1 Dose Selection
Refer to Section 1.5.1 for the dose selection rationale.

3.2.2 Outcome Variable Selection

3.2.2.1 Efficacy
The study is designed primarily to evaluate the efficacy of treatment with sebelipase alfa. The primary efficacy endpoint will be the proportion of subjects surviving to 12 months of age. Secondary survival endpoints will include proportion of subjects surviving to 18 and 24 months of age, and other timepoints, as data permit, and estimated median age at death. Survival rates and median age at death derived from this study will be compared to rates/times reported in the literature and information derived from a natural history study in a similar patient populations (study LAL-1-NH01).

Subjects with untreated early onset LAL Deficiency typically stop growing and this growth failure, in addition to being the predominant clinical feature, is also one of the main contributors to mortality. Improvement in growth is anticipated to be a prerequisite for any beneficial effects of sebelipase alfa on survival. Therefore, secondary efficacy endpoints will include changes from baseline in the following growth parameters:

- Percentiles and/or z-scores, based on WHO child growth standards (WHO Multicentre Growth Reference Study Group, 2006 and 2007), for the following parameters:
  - Weight-for-age (WFA);
  - WFL or WFH;
  - LFA or HFA;
  - Head circumference-for-age (HCFA);
  - Mid-upper arm circumference-for-age (MUACFA).
- Dichotomous growth status indicators for underweight, wasting, and stunting based on WFA, WFL/WFH, and LFA/HFA, respectively (UNICEF, 2009).

Note: Given the switch at age 2 years from measurement of length to measurement of height, growth parameters include weight related to both length and height and age related to both length and height.

A successful therapy for LAL Deficiency presenting in infancy should mitigate the liver and hematological changes associated with the disease. Therefore, the following laboratory parameters will also be included as secondary efficacy endpoints:

- Changes from baseline in aspartate aminotransferase [AST] and ALT levels;
• Normalization of hemoglobin levels without requirement for blood transfusion;
• Changes from baseline in serum ferritin levels.

Additional exploratory efficacy parameters will be investigated to provide supportive evidence of an improvement of LAL Deficiency with sebelipase alfa treatment, and will include changes or percent changes from baseline (or first available assessment if baseline data are unavailable) in:

• Alkaline phosphatase, gamma glutamyltransferase (GGT), albumin, and direct (conjugated), indirect (unconjugated), and total bilirubin levels;
• Liver and spleen size/volume, as measured by ultrasound or magnetic resonance imaging (MRI);
• Hepatomegaly and/or splenomegaly (abdominal girth, liver size, and spleen size) by physical examination;
• Platelet levels;
• Serum lipid levels (total cholesterol, triglycerides, high density lipoprotein [HDL], and LDL).

Because LAL Deficiency presenting in infancy is rapidly progressive and patients often die within 6 months of age (Assmann, 2001, The Metabolic and Molecular Basis of Inherited Disease), information on development is limited in this patient population. The potential extended life expectancy in subjects receiving long-term treatment with sebelipase alfa provides an opportunity to improve the medical community’s understanding of the developmental process in infants with LAL Deficiency treated with sebelipase alfa. To this end, the study will include an exploratory analysis of developmental outcomes, as assessed by the Denver II developmental screening test.

Dietary changes, including discontinuation of a low-fat/low-cholesterol diet and/or introduction of an unrestricted age-appropriate diet, will also be evaluated on an exploratory basis.

Given the potential for ADAs to alter the PD effect of sebelipase alfa, the impact of ADAs on efficacy endpoints will be explored.

3.2.2.2 Safety

The safety and tolerability of treatment with sebelipase alfa, administered by IV infusion, will also be evaluated in this study. Endpoints for safety of sebelipase alfa in infants with LAL Deficiency will include:

• Incidence of AEs, SAEs, and IARs;
• Changes from baseline clinical laboratory tests;
• Changes in vital signs during and post-infusion, relative to pre-infusion values;
• Physical examination findings;
• Use of concomitant medications/therapies;
• Characterization of ADAs, including ADA positivity rate, time to ADA positivity, median and peak ADA titer and time to peak ADA titer.

Given the potential for ADAs to alter the safety profile of sebelipase alfa, the impact of ADAs on safety endpoints will be explored. Further characterization of ADAs, including inhibitory and/or neutralizing ADAs and measurement of specific ADA subtypes (e.g., IgE), may be performed, if appropriate.

3.2.2.3 Pharmacokinetics

The PK of sebelipase alfa in infants with LAL Deficiency will be characterized in this study, blood volume permitting. PK endpoints will include the following sebelipase alfa PK parameters in serum, as data permit:

• maximum observed serum concentration ($C_{\text{max}}$)
• apparent serum clearance (CL)

The impact of ADAs on sebelipase alfa PK will also be explored, if data permit.

3.2.2.4 Pharmacodynamics

Blood samples will also be collected to support exploratory analyses of changes or percent changes from baseline in potential disease-related biomarkers, which may be identified based on emerging information from the sebelipase alfa development program and scientific literature.

3.2.3 Study Duration

The duration of each subject’s treatment in the study is expected to be at least 18 months, and subjects may continue to receive treatment in the study for up to up to 5 years. Therefore, the overall duration of a subject's participation in the study, inclusive of a 3-week screening period and a 4-week follow-up period, may be up to 5 years and 7 weeks.
4 Study Population

4.1 Target Population

The target population for this study is male and female children with growth failure due to LAL Deficiency.

4.2 Number of Subjects

In light of the extremely low prevalence of the target disease, approximately 10 subjects will be enrolled in the study, including a minimum of 8 subjects who are 8 months of age or younger on the date of the first infusion of sebelipase alfa and thus eligible for the primary analysis of survival.

4.3 Inclusion Criteria

A subject must meet all of the following criteria to be eligible to participate in this study:

1. Subject’s parent or legal guardian understands the full nature and purpose of the study, including possible risks and side effects, and provides written informed consent/permission prior to any study procedures being performed.

2. Male or female child with a documented decreased LAL activity relative to the normal range of the lab performing the assay or documented result of molecular genetic testing (2 mutations) confirming a diagnosis of LAL Deficiency.

3. Growth failure* with onset before 6 months of age, as defined by:

   weight decreasing across at least 2 of the 11 major centiles on a standard WHO WFA chart (1st, 3rd, 5th, 10th, 25th, 50th, 75th, 90th, 95th, 97th, 99th);

   OR

   body weight in kg below the 10th centile on a standard WHO WFA chart AND no weight gain for the 2 weeks prior to screening;

   OR

   loss of >5% of birth weight in a child who is older than 2 weeks of age.

*NOTE regarding Inclusion Criterion # 3: In the unusual circumstance where a child has a rapidly progressive course of LAL Deficiency but does not meet growth failure criteria as defined above, the child may be included in the study if the Investigator has substantial clinical concerns based on evidence of the rapid disease progression requiring urgent medical intervention. Inclusion under these exceptional circumstances requires submission of a written summary of the infant’s medical status for review by the Sponsor and must be approved by a written confirmation from the Sponsor after consultation with the SC. The subject must meet all other entry criteria as stated.
4.4 Exclusion Criteria

A subject who meets any of the following criteria will be ineligible to participate in the study:

1. Clinically important concurrent disease or co-morbidities which, in the opinion of the Investigator and Sponsor, would interfere with study participation, including, but not restricted to, congestive heart failure, ongoing circulatory collapse requiring inotropic support, acute or chronic renal failure, additional severe congenital abnormality, or other extenuating circumstances such as life-threatening under nutrition or rapidly progressive liver disease.

2. Subject is >24 months of age. (Note: Subjects >8 months of age on the date of first infusion will not be eligible for the primary efficacy analysis.)

3. Has received an investigational medicinal product other than sebelipase alfa within 14 days prior to the first dose of sebelipase alfa in this study.

4. Myeloablative preparation, or other systemic pre-transplant conditioning, for hematopoietic stem cell or liver transplantation.

5. Previous hematopoietic stem cell or liver transplant.

6. Known hypersensitivity to eggs.

4.5 Concomitant Medication and Treatment

A concomitant medication is any drug or substance taken during the study after the informed consent is signed. Any concomitant medications (including over the counter medications, herbal medications, preventive vaccines, vitamins and food supplements), treatments and procedures (including parenteral feeds, surgery, or physical therapy) received by the subject through completion of the follow-up visit, approximately 30 days after the last dose of IMP, must be recorded in the electronic case report form (eCRF). A description of the type of drug or procedure, the amount, duration, reason for administration of drug and the outcome of any procedure must be documented. Adverse events (AEs) related to the administration of a concomitant medication or the performance of a procedure must also be documented on the AE page of the eCRF.

Information about a subject's diet prior to initiation of treatment with sebelipase alfa in this study or under an expanded access program, and any changes in a subject's diet during treatment in this study (e.g., discontinuation of a low-fat/low-cholesterol diet and/or introduction of an unrestricted age-appropriate diet) will be recorded in the eCRF.

4.6 Discontinuation of Subjects from Treatment or Assessment

4.6.1 Premature Withdrawal from Study Participation

In accordance with the Declaration of Helsinki, subject’s parent or legal guardian have the right to withdraw from the study at any time for any reason.
The Investigator and Sponsor also have the right to withdraw subjects from the study at any time. Specific reasons for discontinuation may include but are not restricted to the following:

- Intercurrent illness;
- Medically significant AEs;
- Protocol deviation or non-compliance;
- Termination of the study by the Sponsor.

Unnecessary withdrawals should be avoided as an excessive rate of withdrawal can render the study uninterpretable.

4.6.2 Procedures for Discontinuation

A subject’s parent or legal guardian is free to withdraw consent and/or discontinue the subject’s participation in the study at any time, without prejudice to further treatment. A subject’s participation in the study may also be discontinued at any time at the discretion of the Investigator or Sponsor. Should a subject’s parent or legal guardian decide to withdraw consent, all efforts will be made to complete and report the observations as thoroughly as possible. The parent or legal guardian of subjects who are discontinued from the study should be asked about the reason(s) for their discontinuation and about the presence of AEs. The date and the reason for discontinuation will be recorded in the eCRF. Subjects who discontinue prior to IMP administration will be replaced.

Subjects who are prematurely withdrawn from the study will be asked to complete all discontinuation assessments prior to withdrawal (see Appendix A), if possible. Information on the survival of discontinued subjects will be collected until completion of the study. Serious AEs will be followed according to Section 7.2.3 and reported according to Section 7.4. A subject will be considered early terminated if the subject does not complete the study after enrollment. A subject will be considered discontinued due to an AE if the subject received any infusion or partial infusion of the investigational medicinal product, but did not complete the study because of an AE, whether or not considered drug related. At the end of the subject’s participation in the study, the Investigator will document the reason(s) for study discontinuation in the eCRF.

In the event that a subject dies, permission will be sought (through a separate informed consent form) from the subject’s parent or legal guardian for an autopsy. Samples collected from these procedures will be used to further understand LAL Deficiency and the effect of sebelipase alfa.

When a subject fails to return for scheduled assessments, the following efforts should be made to contact his/her parent or legal guardian to determine a reason for the failure to return: 3 phone attempts, including the date and time, to be documented in the subject’s chart. If there is no response to the phone calls, a certified letter should be sent. After these efforts have been exhausted, a subject should be identified as lost to follow-up in the eCRF.

4.7 Subject Replacement Policy

Subjects are not replaced per se in this study. If a subject who qualifies for the Primary Efficacy Analysis Set discontinues the trial prematurely before receiving at least 4 infusions of
sebelipase alfa, an additional subject may be enrolled, at the discretion of the Sponsor, to achieve a minimum of 8 subjects who have at least 4 infusions.

4.8 Subject Recruitment and Screening
 Subjects may be recruited into the study directly from the Investigators’ or sub-investigators’ clinical practices, or referred to the investigative sites from other clinics. Information about the study will be posted on the http://clinicaltrials.gov/ and https://www.clinicaltrialsregister.eu/ websites.

Subject screening should occur between 1 and 21 days prior to the infusion at Week 0 (Day 0).
5 Schedule of Assessments and Study Procedures

The schedule of assessments is presented in Appendix A.

Subjects who are clinically stable enough to tolerate general anesthesia may be considered for central line placement for long-term vascular access, in accordance with institutional guidelines. Magnetic resonance imaging (MRI) should be considered for subjects receiving general anesthesia and/or sedation for central line placement or for other procedures (see Section 5.1.8).

European Medicines Agency (EMA) recommended blood volume limits should be used as a guidance for blood sampling in this study: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003754.pdf. Per individual, the study-related blood loss should not exceed 3% of the total blood volume during a 4-week period or 1% of total blood volume at any single time. The actual situation of the child (sleep/activity, severity of anemia, and hemodynamic state) must permit such blood sampling. Table 1 summarizes mean blood volume per body weight based on an individual’s age. Assuming a total blood volume of 80 mL/kg body weight for an average patient in this study, 3% of total blood volume corresponds to 2.4 mL/kg body weight and 1% of total blood volume corresponds to about 0.8 mL/kg body weight.

<table>
<thead>
<tr>
<th>Age</th>
<th>Mean blood volume per weight (mL/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborn, 24 hours</td>
<td>83.3</td>
</tr>
<tr>
<td>Children, 3 months</td>
<td>87</td>
</tr>
<tr>
<td>Children, 6 months</td>
<td>86</td>
</tr>
<tr>
<td>Children, 1 year</td>
<td>80</td>
</tr>
<tr>
<td>Children, 6 years</td>
<td>80</td>
</tr>
<tr>
<td>Children, 10 years</td>
<td>75</td>
</tr>
<tr>
<td>Children, 15 years</td>
<td>71</td>
</tr>
</tbody>
</table>

Source: Geigy Scientific Tables, 7th Ed.

5.1 Study Assessments

5.1.1 Informed Consent

The parent or legal guardian of a potential subject will be given a verbal explanation of the study and the procedures involved and will have all questions addressed. The subject’s parent or legal guardian must sign and date a consent form that has been approved by the appropriate institutional review board/independent ethics committee (IRB/IEC) before the screening procedures are initiated. The subject’s parent or legal guardian will be given a copy of the signed and dated informed consent form.

5.1.2 Subject Eligibility

All subjects will be assessed for eligibility against the inclusion and exclusion criteria described in Section 4.3 and Section 4.4 and background clinical information collected.
5.1.3 Medical History
Complete medical history, including prenatal, birth history, family history and disease history will be recorded at Screening.

5.1.4 Demographic Information
The following demographic information will be collected at Screening: date of birth, birth weight, gender, race and ethnicity.

5.1.5 Anthropometrics
Anthropometrics, including weight, recumbent length (subjects ≤2 years of age at the time of examination) or height (subjects >2 years of age at the time of examination), head circumference, mid-upper arm circumference, and abdominal circumference, will be measured at the timepoints specified in Appendix A.

Refer to the SOM for a detailed description of the procedure for each anthropometric measurement.

Percentiles or z-scores for WFA, WFL/WFH, LFA/HFA, HCFA, and MUACFA will be determined based on WHO child growth standards (WHO Multicentre Growth Reference Study Group, 2006 and 2007). Growth status will also be classified according to 3 dichotomous indicators: underweight (<-2 standard deviations [SD] from the median for WFA), wasting (<-2 SD from the median for WFL/WFH), and stunting (<-2 SD from the median for LFA/HFA).

5.1.6 Physical Examination
A physical examination will be performed by the Investigator or qualified designee at the timepoints specified in Appendix A. The examination will include an assessment of the subject’s general appearance, skin, head, eyes, ears, nose, and throat, heart, lungs, abdomen, extremities/joints, and neurological status. Whenever possible, the same person should perform the physical examination at each study visit. Abnormal findings will be captured in the eCRF.

Every physical examination will also include the following:

- **Liver size**: A clinical assessment of liver size (palpable/non palpable and centimeters below costal margin), regularity (smooth/nodular) and sensitivity (tender/non tender) will be made.

- **Spleen size**: A clinical assessment of spleen size (palpable/non palpable and centimeters below costal margin), regularity (smooth/nodular) and sensitivity (tender/non-tender) will be made.

- **Lymphadenopathy**: An assessment of the size, location, and character of any palpable lymph nodes will be made. Areas to be examined include: cephalic (occipital, preauricular, postauricular, submental, submandibular), cervical, clavicular, axillary, and inguinal. Any enlarged nodes will be characterized as tender or non-tender.
- **Digital Photograph**: A digital photographic image of the subject in a supine position (full length and abdominal close up) will obtained during selected physical examinations, as specified in Appendix A.

Refer to the Site Operations Manual (SOM) for a detailed description of the physical examination procedure and instructions for photographs.

### 5.1.7 Abdominal Ultrasound

Abdominal ultrasonography will be performed at the timepoints specified in Appendix A to measure the liver and spleen size.

Abdominal ultrasonography will be performed by a qualified person, and results will be interpreted by a radiologist trained in ultrasonography.

### 5.1.8 Abdominal MRI

Abdominal MRIs should be considered at the timepoints specified in Appendix A to provide a more accurate quantification of liver and spleen volume. If an Abdominal MRI cannot be performed, an Abdominal Ultrasound will be performed instead at that timepoint.

Investigators are encouraged to obtain abdominal MRIs in subjects receiving general anesthesia or sedation for other procedures at a scheduled imaging timepoint. To allow flexibility in scheduling MRIs, a broad time window is given for each MRI assessment in Appendix A. For example, the baseline MRI may be obtained at any time from Screening through the Week 0 study visit.

Because MRI can provide important information on liver and spleen volume that can be related to expected normal values abdominal MRIs should be obtained during the treatment phase, even if a subject did not provide a baseline MRI.

All imaging scans will be acquired and the results interpreted by a magnetic resonance technician or other qualified individual using standardized imaging protocols.

Refer to the Imaging Manual for instructions on image acquisition and analysis.

### 5.1.9 Vital Signs

Vital signs will include pulse rate, respiratory rate, systolic and diastolic blood pressure and core body temperature (rectal or oral). Assessment of pulse rate and blood pressure will be taken after the subject has been in a supine position.

Vital signs will be measured at the timepoints specified in Appendix A. On dosing days, vital signs will initially be recorded pre-infusion, every 15 (±5) minutes during infusion and every 30 (±10) minutes from 0 to 4 hours after completion of the infusion. Once a subject has received a stable dose for at least 2 months, with no moderate-to-severe IARs, vital signs will be recorded pre-infusion and every 30 (±10) minutes during infusion and from 0 to 4 hours after completion of the infusion. After a subject has successfully completed at least 1 year of treatment with no occurrence of moderate-to-severe IARs, the post-infusion period for vital sign monitoring may be shortened from 4 hours to 2 hours.
Additional readings may be taken at the discretion of the Investigator and in the event of an IAR.

### 5.1.10 Electrocardiogram

An age-appropriate 12-lead electrocardiogram (ECG) will be obtained at Screening and reviewed by a qualified clinician. Additional age-appropriate 12-lead ECGs may be obtained at subsequent study visits, if clinically indicated. Any abnormalities identified by the clinician will be specified as clinically significant or not clinically significant.

### 5.1.11 Laboratory Assessments

Blood and urine samples for laboratory tests will be collected at the timepoints specified in Appendix A.

Prior to any dose change, serum lipid, serum liver, hematology, chemistry, ferritin and hs-CRP shall be obtained. Serum lipid and serum liver assessments should be taken 4, 8, and 12 weeks following any study drug or lipid drug dose change.

Due to the limitations on the volume of blood collection that is considered to be acceptable in young children with very small total circulating blood volumes (see Section 5), the laboratory samples will be ranked in the order corresponding to the study objectives, as shown in Table 2. Only Tier 1 assessments are considered mandatory and all efforts should be made to collect these in all subjects. Samples for the Tier 2 and Tier 3 assessments will only be collected if the blood volume threshold for subject’s weight, as well as the subject’s clinical status, permit (see Section 5 for further details).

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Clinical Laboratory Tests, By Tier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tier 1 (Mandatory)</td>
<td></td>
</tr>
<tr>
<td>CBC/Hematology:</td>
<td>White blood cell count, red blood cell count, hemoglobin, hematocrit, MCV, MCH, MCHC, platelet count, neutrophil, lymphocytes, monocytes, eosinophils, basophils, peripheral smear for examination of cell morphology</td>
</tr>
<tr>
<td>Chemistry Panel:</td>
<td>Glucose, urea nitrogen, creatinine, sodium, potassium, chloride, calcium, magnesium, inorganic phosphorus, total protein, lactate dehydrogenase</td>
</tr>
<tr>
<td>Liver Function Tests:</td>
<td>AST/SGOT, ALT/SGPT, alkaline phosphatase, GGT, albumin, bilirubin (direct, indirect, total)</td>
</tr>
<tr>
<td>Anti-drug Antibody:</td>
<td>Anti-sebelipase alfa antibody</td>
</tr>
<tr>
<td>Urinalysis:</td>
<td>pH, glucose, ketones, blood, protein, nitrite, and leukocytes (microscopic examination will only be done if blood, nitrite and/or leukocytes are abnormal)</td>
</tr>
</tbody>
</table>
Coagulation Studies: PT (INR), aPTT

DNA Sample See Section 5.1.15

LAL Enzyme Activity See Section 5.1.16

Tier 2 (Optional)

Lipid Panel: Total cholesterol, triglyceride, HDL, LDL

Other Chemistry: Serum ferritin

Tier 3 (Optional)

Pharmacokinetic Assessments See Section 5.1.14

Exploratory Biomarkers See Section 5.1.13

Coagulation studies are required at Screening only. Thereafter, they should be completed only if the preceding assessment was abnormal or if it is clinically indicated based on emerging evidence of liver dysfunction.

Laboratory reports will be reviewed by the Investigator, or designee, and any abnormalities will be specified as clinically significant or not clinically significant. In the event of unexplained clinically significant abnormal laboratory test values, the tests should be repeated as soon as possible (preferably within 24 hours) and followed up until they have returned to within the normal range and/or an adequate explanation has been identified.

Refer to the laboratory manual for further details regarding the collection, processing, and storage of these samples.

5.1.12 Denver II Developmental Screening Test

The Denver II will be administered at the timepoints specified in Appendix A.

The Denver II is a standardized measure to assess development in children from 1 month to 6 years of age (Frankenberg, 1992, Pediatr). The Denver II includes performance-based and parent-reported items in 4 functional areas: fine motor-adaptive, gross motor, personal-social, and language skills. The test was normed on a diverse sample of children who were full term and had no obvious developmental disabilities; the norms indicate when 25%, 50%, 75%, and 90% of children passed each item. The Denver II has good inter-rater and test-retest reliability (correlations ≥ 0.90 for most tests).

The Denver II must be administered by a trained clinician and takes an average of 10 to 20 minutes to complete. Administration and scoring of the Denver II is based upon the child's age. (Note that for premature infants, the number of months premature is subtracted from the infant's chronological age.) For each test item administered, the clinician determines if the child's response falls within or outside of the normal expected range of success on that item for the child's age. The interpretation of the individual test items is then used to classify the child's development in each functional area and for the overall test.
5.1.13 Exploratory Biomarkers
Whenever feasible, based on the blood volume threshold for the subject’s weight, a blood sample for serum isolation (2 aliquots) will be obtained at the timepoints specified in Appendix A. The serum sample will be used to identify baseline disease and dynamic markers that will help better understand the pathogenesis of LAL Deficiency, related comorbidities and response to treatment. Given the rarity of LAL Deficiency and the paucity of information on disease characteristics, the definitive list of analytes remains to be determined.

Refer to the laboratory manual for further details regarding the collection, processing, and storage of these samples.

5.1.14 Pharmacokinetic Assessments
To reduce risk of iatrogenic anemia, PK sampling may be limited. In order of importance samples will be collected to derive $C_{\text{max}}$ and $CL$.

PK samples should not be taken from the same extremity where the infusion catheter is in place. Sampling for measurement of sebelipase alfa serum levels will be performed during the study visits indicated in Appendix A. These samples will be collected within designated time windows, rather than at discrete timepoints, to allow more flexibility in the management of PK sampling in these subjects and to provide opportunities for measurement of drug concentrations across a broader timeperiod with limited sampling.

In all subjects:
- 0 to 1 hours after the start of the infusion;
- Between 1 hour after the start of the infusion and the end of the infusion (i.e. when the infusion bag has been emptied, but prior to the sodium chloride flush).

In those subjects for whom the thresholds for allowed blood collection volumes have not been exceeded:
- 0 to 0.5 hours after completion of the infusion;
- 0.5 to 1 hour after completion of the infusion;
- 1 to 2 hours after completion of the infusion.

All PK samples, at time points that coincide with a vital sign assessment, will be taken before cuff inflation for blood pressure assessment on the non-infusion arm. PK samples at other time points will be taken at least 5 minutes after cuff deflation.

Refer to the laboratory manual for further details regarding the collection, processing, and storage of these samples.

5.1.15 DNA Sample
The Sponsor intends to apply pharmacogenetics to the sebelipase alfa program in order to explore how genetic variations may affect clinical parameters associated with sebelipase alfa use and acid lipase biology. DNA sequences, including both the protein coding sequence and
sequences that regulate gene transcription, messenger ribonucleic acid (mRNA) stability and the efficiency of protein translation that may be investigated include:

1. LAL (LIPA);
2. Genes coding for other proteins involved in lipid biology that may contribute to and/or modify the disease phenotype of LAL Deficiency, e.g. ABCA1;
3. Genes that may modify susceptibility to any sebelipase alfa related AEs.

Where possible and in compliance with local regulations, a blood sample for DNA extraction will be collected from the subject at Screening or as soon as practically possible thereafter based on blood volume collection threshold, unless a stored DNA sample is already available for the subject. The DNA will be stored and used as part of a later pooled analysis. This will include determining the spectrum of LAL mutations in subjects with growth failure due to LAL Deficiency and the relationship between gene mutation, safety, efficacy and susceptibility to anti-sebelipase alfa antibody development.

If feasible, a blood sample for DNA extraction and testing of the LAL gene mutations will be collected from the subjects’ biological parents after a separate consent has been obtained.

The Sponsor will only analyze DNA sequences within genes relevant to the mode of action and response to sebelipase alfa, including variants important in understanding AEs, and candidate genes with a potential role in the etiology, pathogenesis, and progression of LAL Deficiency.

Samples will be stored by the Sponsor, or designee, in a secure, monitored, and controlled environment. No additional testing will be performed on the samples collected in the study.

Refer to the laboratory manual for further details regarding the collection, processing, and storage of these samples.

5.1.16 LAL Enzyme Activity
Study inclusion will be contingent on documented decreased LAL activity relative to the normal range of the lab performing the assay or a documented result of molecular genetic testing confirming a diagnosis of LAL Deficiency.

Blood samples will also be collected at Screening to measure LAL activity in peripheral blood mononuclear cells (PBMCs) and in a dried blood spot (DBS) collected on filter paper to ensure consistency of LAL activity measurement in all subjects. In the unlikely event of a discrepancy between the diagnosis of LAL Deficiency based on baseline LAL activity in PBMCs and/or DBS and the previously documented diagnosis, a subject may be discontinued from the study and may be replaced.

5.1.17 Liver Biopsy
An optional liver biopsy will be obtained for evaluation of hepatic histology after at least 1 year of treatment, at the timpoints suggested in Appendix A. Biopsies will be performed only with consent from the subject’s parent/guardian and where local regulations permit, and are subject to discretionary approval from each center’s IRB/IEC.
Liver biopsy procedures should be performed according to the local institutional practices by a qualified professional.

All biopsies collected in this study will be centrally evaluated by a pathologist with the appropriate expertise. This evaluation will include an assessment of the overall disease activity as well as a description of specific histopathological features of the disease.
6 Investigational Medicinal Product

6.1 Description of IMP
Details of the non-clinical experience to date with sebelipase alfa, as well as IMP stability information, can be found in the current version of the Investigator Brochure (IB). Sebelipase alfa must be administered under close supervision of the Investigator, or designee.

Sebelipase alfa is provided in single dose 10 mL glass vials. The solution (total 10.5 mL including 5% overfill) has an approximate concentration of 2 mg/mL. Exact concentration will be on the individual vials.

Sebelipase alfa contains no preservatives and vials are single use only.

Sodium chloride (0.9%) for injection, for use in preparation of diluted solutions for infusion, will be sourced locally by the study center.

6.2 Method for Assigning Subjects to Treatment Groups
No randomization schemes will be employed; all subjects will receive the same starting dose of sebelipase alfa in this study.

Each subject will be assigned an enrollment number after informed consent has been obtained from the subject's parent or legal guardian. This enrollment number will be used to identify the subject throughout his/her participation in the study.

A subject who does not meet all study eligibility criteria due to a potentially transient condition observed at screening (e.g., discontinuation of another investigational medicinal product within 14 days, or failure to meet protocol-defined growth failure criteria in a subject <6 months of age), will be allowed to return for re-screening.

6.3 Storage and Disposition of IMP

6.3.1 Receipt of IMP
Upon receipt of the IMP, an inventory must be performed and verified by the person accepting the shipment. It is important that upon IMP delivery the designated study staff counts and verifies that the shipment contains all the items noted in the shipment inventory. Any damaged or unusable IMP in a given shipment will be documented in the study files. The Investigator must notify study Sponsor of any damaged or unusable IMP that was supplied to the Investigator's site.

6.3.2 Storage
All sebelipase alfa vials must be stored under controlled refrigerated conditions at 2°C to 8°C (36°F to 46°F). (Note: temperature excursions up to 25°C for up to 12 hours have not been shown to be associated with loss of enzyme activity.) Vials should not be frozen and should be protected from light during storage.
The infusion bag or syringe containing sebelipase alfa diluted in 0.9% sodium chloride should be prepared just prior to the start of infusion administration. For study sites where there is a requirement for dilution at a separate location this needs to be done in a place with controlled and aseptic conditions. Although the infusion bag or syringe is stable at room temperature (23°C to 26°C) for 12 hours, it should be used as soon as possible after preparation.

6.3.3 Disposition
The Investigator or designated person (e.g. a licensed pharmacist) will be responsible for maintaining accurate records for all IMP used. Opened sebelipase alfa vials still containing any residual volume may be stored at room temperature for IMP accountability. Following IMP accountability, the Sponsor or designee will give written authorization to the Investigator to return or destroy any remaining IMP as instructed.

6.4 Preparation and Administration of IMP
Under no circumstances will the IMP be used other than as directed in the protocol.

6.4.1 Preparation of IMP
The infusion bag (or syringe) containing sebelipase alfa will be prepared just prior to the start of infusion administration. Prior to preparation of the infusion, the vials of study drug will be visually inspected. The solution should not be used if it contains foreign particulate matter or is discolored. The solution may be used if a small number of visible translucent to opalescent or white amorphous or threadlike particles are present in the vial. The contents should NOT be warmed using a microwave or other heat source. Sebelipase alfa is a protein and will be handled and mixed gently to prevent foaming.

If subject’s weight cannot reliably be obtained on the morning of the infusion then the subject’s most recent weight measurement within 7 days, rounded to the nearest 0.1 kg, will be used for calculating the volume of study drug to be withdrawn from the vial(s) to prepare the infusion. Sebelipase alfa should be diluted to a concentration of 0.1 to 1.5 mg/ml for infusion. Refer to the IMP manual for detailed instructions regarding preparation.

6.4.2 Administration of IMP
Sebelipase alfa should not be infused with other products in the same infusion tubing, as the compatibility in solution with other products has not been evaluated. IMP infusions will be administered at an infusion rate depending on the subject’s weight, and must be administered under close supervision of the Investigator, or designee. Sebelipase alfa should not be administered at an infusion rate exceeding 4 ml/kg/hr. For detailed administration instructions please refer to the IMP manual.

Subjects who are medically stable, as determined by the Investigator, may transfer to a local medical center for long-term treatment, contingent upon the local medical center being appropriately qualified and securing the required regulatory and IRB/IEC approvals. Scheduled
study assessments may also be performed at a local medical center with access to the appropriate facilities and expertise.

6.5 Infusion Associated Reactions

Infusion-associated reactions will be considered AEs of special interest. Any AE that occurs during the infusion or within 4 hours after the IMP infusion is completed and is assessed by the Investigator as at least possibly related to IMP will be designated as an IAR. In addition, if, at any time during the study, the Investigator observes symptoms that he/she considers to be consistent with an IAR or hypersensitivity reaction related to administration of study drug, the symptoms should be recorded as an AE(s) and designated as an IAR(s). Individual adverse event terms should be recorded rather than the terms, IAR or Infusion Associated Reaction.

As with any ERT, medications and equipment for the treatment of hypersensitivity reactions must be available for immediate use in case of unexpected, severe hypersensitivity reactions. These supplies include, but are not limited to, oxygen, acetaminophen, antihistamines (e.g., diphenhydramine, parenteral and oral [PO]), corticosteroids, epinephrine and cardiopulmonary resuscitation devices.

General guidelines for classifying the severity of a reaction are provided in Section 7.1.1.

For similar biological products, most acute IARs occur within 2 hours of the infusion. Signs of a possible acute IAR may include:

- Hyperemia (flushing), fever and/or chills, nausea, pruritus, urticaria, gastro-intestinal symptoms (vomiting, diarrhea, abdominal cramping) cardiopulmonary reactions, including chest pain, dyspnea, wheezing, stridor, hypotension or hypertension.

If any of the above signs and symptoms are observed during the infusion and the subject remains hemodynamically stable:

- The infusion rate must be slowed by 50% (reduced to half the rate being given at the onset of the event, e.g. from 10 mL/hr to 5 mL/hr) and the infusion time extended in accordance with the institutional standard of care. The infusion rate may be decreased further by 25% if symptoms persist. If the event resolves, the infusion should continue for a minimum of 30 minutes at the reduced rate before the rate is increased to 75% of the original rate on the infusion schedule. If the subject tolerates infusion at 75% of the original rate for at least 30 minutes the original rate may be restored for the remainder of the infusion.
- In accordance with institutional standard of care for subject’s age, treatment with oral anti-pyretic and/or antihistamine should be considered.

In subjects who experience severe IAR with clinically significant cardiovascular effects (e.g., hypertension or hypotension defined as a decline approaching 20-30% of their preinfusion value without alternative etiology, agitation, pain, fluid overload, dehydration), respiratory symptoms (significant shortness of breath, stridor, wheezing, laryngeal edema or swelling of tongue),
cardiac arrhythmias, or anaphylactic/anaphylactic shock with hypotension and circulatory collapse:

- The infusion should be stopped.
- The subject should be treated with oxygen if available, IV antihistamines, corticosteroids, and IM epinephrine, if necessary, in accordance with institutional standard of care for the subject's age.
- Dosing of the subject will be suspended until the Safety Review Committee has completed review of the IAR, and any other relevant safety data.
- Subjects who experience a moderate or severe IAR should have a serum sample collected for tryptase 1-3 hours after the IAR onset and another serum sample for tryptase and ADA during the next study visit (>4 days after the IAR) prior to the infusion. Skin testing may be considered.

Additional details on the management of subjects with infusion reactions are outlined in the table in Appendix B.

### 6.6 Blinding of IMP

This is an open label study with no requirement for blinding.

### 6.7 Destruction of IMP

Following IMP accountability and written permission from the Sponsor to destroy IMP, documentation of destruction must contain, at a minimum, the following:

- Identity, lot number or subject number;
- Quantity;
- Date of destruction;
- Method of destruction;
- Name and signature of person or company responsible for destruction.
7 Assessment of Safety
The methods for collecting safety data are described below.

7.1 Adverse Events and Laboratory Abnormalities

7.1.1 Clinical Adverse Events

Adverse Event

An Adverse Event is any untoward medical occurrence in a subject which does not necessarily have to have a causal relationship with the administration of an IMP. An AE can therefore be any unfavorable and unintended sign, symptom or disease temporally associated with the use of the IMP, whether or not considered related to the medicinal product. Pre-existing conditions that worsen in severity during the course of the study are to be reported as AEs.

All AEs occurring during the clinical study will be reported on the AE page of the eCRF as described in Section 7.3.

The Investigator will assess the severity, causality (relationship to IMP), and seriousness of each AE.

Severity: The severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 or higher. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on the general guideline below. Detailed instructions on grading of events by Medical Dictionary for Regulatory Activities (MedDRA) system organ class and lower level term are available online.

- **Grade 1** Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
- **Grade 2** Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily life (e.g., preparing meals, shopping for groceries or clothes, using the telephone, managing money).
- **Grade 3** Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily life (e.g., bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden).
- **Grade 4** Life-threatening consequences; urgent intervention indicated.
- **Grade 5** Death related to AE.

Causality: AEs will be assessed by the Investigator as not related, unlikely related, possibly related, or related to IMP. Table 3 provides general guidance on the assessment of causality. Assessment of causality should be based on the Investigator’s medical judgment and the observed symptoms associated with the event. For data reporting purposes, related AEs will be
those assessed by the Investigator as possibly related or related to IMP, and unrelated AEs will be those assessed by the Investigator as not related or unlikely related to IMP.

Table 3 Assessment of Causality

<table>
<thead>
<tr>
<th>Relationship to IMP</th>
<th>Criteria for Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Related</td>
<td>Reasonable temporal relationship of the clinical event to IMP administration AND cannot be reasonably explained by other factors (such as the subject’s clinical state, concomitant therapy, and/or other interventions).</td>
</tr>
<tr>
<td>Possibly Related</td>
<td>The temporal relationship of the clinical event to IMP administration makes causal relationship possible but not unlikely AND other drugs, therapeutic interventions or underlying conditions do not provide a sufficient explanation for the observed event.</td>
</tr>
<tr>
<td>Unlikely Related</td>
<td>The temporal relationship of the clinical event to IMP administration makes causal relationship unlikely but not impossible AND other drugs, therapeutic interventions or underlying conditions provide a plausible explanation for the observed event.</td>
</tr>
<tr>
<td>Not Related</td>
<td>Data are available to clearly identify an alternative cause for the reaction.</td>
</tr>
</tbody>
</table>

Seriousness: AEs will be classified as serious or non-serious according to the definitions provided below.

**Serious Adverse Event**

A **serious adverse event** is any AE that results in any of the following outcomes:

- Death
- Immediately life threatening
- Requires inpatient hospitalization or prolongation of existing hospitalization
- Results in congenital anomaly/birth defect
- Results in a persistent or significant disability or incapacity
- An important medical event that may not result in death, be life threatening, or require hospitalization may be considered an SAE when, based upon appropriate medical judgment, the event may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed.

All AEs that do not meet any of the criteria for serious, should be regarded as **non-serious adverse events**. Given the severity and life threatening nature of LAL Deficiency in infants, it is likely that these subjects will be hospitalized during the first several weeks on study.
Continuation of this initial hospitalization for participation in the trial is not considered an SAE. Also, a hospitalization to accommodate a study procedure is not considered an SAE. However, during the hospitalization, AEs will be collected and assessed for seriousness & reported appropriately (e.g., important medical event or prolonged hospitalization).

All SAEs and IARs must be reported to the Sponsor as described in Section 7.4.

7.1.2 Laboratory Test Abnormality

Laboratory test results will be recorded on the laboratory page of the eCRF. Out of range laboratory test values will be reported as AEs (on the AE page of the eCRF) if they are considered to be clinically significant abnormalities by the Investigator and represent a change from the subject’s baseline values.

7.2 Handling of Safety Parameters

7.2.1 Serious Adverse Events and Infusion-Associated Reactions (Immediately Reportable to the Sponsor)

All SAEs and IARs, irrespective of the treatment received by the subject, must be reported to the Sponsor or designee immediately and no later than 24 hours of the Investigator’s first knowledge of the event (expedited reporting).

7.2.2 Adverse Event Reporting Period

The study period during which AEs must be reported is defined as the period from the signature of informed consent to the end of the study treatment follow-up. AEs occurring after signing the informed consent but prior to the first dose of study medication will only be recorded if assessed as related to protocol procedures or requirements. For this study, the study treatment follow-up is defined as a minimum of 30 days after the last dose of IMP. If a subject experiences an SAE that is considered to be related to study treatment at any time after the study, it must be reported to the Sponsor.

7.2.3 Treatment and Follow-up of Adverse Events

During the study, all AEs and SAEs will be followed up until they have returned to baseline status or stabilized or until the Investigator and Sponsor or designee agree that follow up is no longer necessary. If a clear explanation is established, it should be documented.

Treatment of AEs is at the discretion of the Investigator, and should follow the standards of medical care at the Investigator’s institution.

7.2.4 Follow-up of Abnormal Laboratory Test Values

In the event of unexplained clinically significant abnormal laboratory values, the tests should be repeated and followed up until they have returned to baseline values and/or an adequate explanation of the abnormality is found. If a clear explanation is established, it should be documented.
7.2.5 Pregnancy
Subjects in this study will be of non-reproductive potential.

7.3 Recording of Adverse Events
At each contact with the subject (and the subject’s parent or legal guardian), the Investigator must seek information on AEs by specific questioning and, as appropriate, by examination. Information on all AEs should be recorded immediately in the source documentation, and in the eCRF. All clearly related signs, symptoms, and abnormal diagnostic procedures results should be recorded under one diagnosis.

AEs will be recorded from the time of signing of the informed consent until completion of the last scheduled visit, i.e., the follow-up visit. AEs occurring after signing the informed consent but prior to the first dose of study medication will only be recorded if assessed as related to protocol procedures or requirements. Any AEs remaining unresolved at the completion of the last scheduled visit should be recorded as ongoing. Ongoing AEs/SAEs should continue to be followed up for the period specified in Section 7.2.2 but without further recording in the eCRF. However, follow-up information on SAEs must be reported to the Sponsor or designee as described in Section 7.4.1. Any SAE that occurs after the study period and is considered to be related to the study treatment or study participation should be recorded and reported immediately.

Any AE that occurs within 24 hours of the infusion will be recorded by time and date, AEs occurring 24 hours after the infusion will be recorded by date only. The date and time, or the date when the AE started and stopped, as well as the intensity, seriousness, action taken with regard to the study treatment, causality assessment and outcome of the event will be recorded for each AE.

7.4 Reporting of Serious Adverse Events and Unanticipated Problems
Investigators and the Sponsor must conform to the AE reporting timelines, formats and requirements of the various entities to which they are responsible. (§13 GCP-V; Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use [‘CT-3’]; US CFR Title 21, §312.32, Investigational New Drug [IND] safety reporting). The Sponsor or designee will report all reportable events to all regulatory authorities and Investigators as required by local regulations.

All SAEs, IARs, and other reportable events (see Section 7.4.3) must be reported to the Sponsor or designee in an expedited manner according to timelines described in Section 7.4.1.

Periodic Safety reporting to competent authorities will be done by the Sponsor according to national and local regulations.
7.4.1 Investigator Reporting: Notifying the Study Sponsor
Any SAE, IAR or unanticipated problem posing risk of harm to subjects, must be reported to the Sponsor, or designee immediately, and no later than 24 hours of the Investigator’s first knowledge of the event. To report such events, a SAE/IAR form must be completed by the Investigator and sent to the study Sponsor or designee within 24 hours. The Investigator will keep a copy of this SAE or IAR form on file at the study site.

The Investigator must promptly provide further information on the SAE, IAR, or the unanticipated problem. This should include a copy of the completed SAE or IAR form, and any other diagnostic information that will assist the understanding of the event. Significant new information on ongoing SAEs or IARs must be reported to the Sponsor or designee immediately and no later than 24 hours of the Investigator’s knowledge.

Report SAEs and IARs by phone, fax or email to:

<table>
<thead>
<tr>
<th>For cases in North America</th>
<th>For cases in Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phone: PPD</td>
<td>Fax: PPD</td>
</tr>
<tr>
<td>Fax: PPD</td>
<td>Email: PPD</td>
</tr>
</tbody>
</table>

7.4.2 Investigator Reporting: Notifying the IRB/IEC
Unanticipated problems posing risks to subjects or others as noted above will be reported to the IRB/IEC according to local regulations. Copies of each report and documentation of IRB/IEC notification and acknowledgement of receipt will be kept in the Investigator’s study file.

7.4.3 Sponsor Reporting: Notifying Regulatory Authorities
The study Sponsor is required to report certain study events in an expedited fashion to the Food and Drug Administration (FDA), the EMA and to all country Regulatory Authorities where the study is being conducted. The following describes the safety reporting requirements by timeline for reporting and associated type of event:

**Immediately and within 7 calendar days**
- Any suspected adverse reaction that is associated with the use of the study drug, unexpected, and fatal or life threatening.
- Follow-up information must be reported in the following 8 days.

**Immediately and within 15 calendar days**
- Any suspected adverse reaction that is associated with the use of the study drug, unexpected, and serious, but not fatal or life threatening
- Any finding from tests in laboratory animals that suggest a significant risk for human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity
- Any event in connection with the conduct of the study or the development of the IMP which may affect the safety of the trial subjects.
- Follow-up information must be reported within 15 calendar days

The Sponsor will comply with all additional local safety requirements, as applicable. Periodic safety reporting to competent authorities will be done by the Sponsor or designee according to national and local regulations.

### 7.4.4 Sponsor Reporting: Notifying Participating Investigators

It is the responsibility of the study Sponsor to immediately notify all participating Investigators, in addition to any suspected AE associated with the use of the drug that is both serious and unexpected, as well as any finding from tests in laboratory animals that suggest a significant risk for human subjects.

### 7.5 Dose Modification and Stopping Rules

Upon a recommendation from the independent SC (see Section 7.6.1), the Sponsor may suspend dosing for an individual subject or all subjects enrolled in the study, at any time, due to poor tolerance or potential safety risks.

Specific rules for suspending dosing in an individual subject are provided in Appendix C.

### 7.6 Medical Monitoring

It is the responsibility of the Investigator to oversee the safety of the study at his/her site. This safety monitoring will include a thorough assessment and appropriate reporting of AEs as noted above, as well as the construction and implementation of a site data and safety-monitoring plan (see Section 10). Medical monitoring will include a regular assessment of the number and type of SAEs.

#### 7.6.1 Independent Safety Committee

The oversight of the subject safety in the study will be provided by an independent Safety Committee. The activities and composition of the SC will be outlined in the SC Charter which will be ratified during the initial meeting, prior to commencement of dosing of the study subjects. The SC will be tasked with ongoing review of safety and efficacy data in order to advise the study Investigators regarding dose continuation and dose escalation decisions for the study (see Section 3.1 for details). The SC will be comprised of a group of individuals with pertinent medical expertise that reviews, on a regular basis, the conduct of this study and the emergent safety data. This SC will provide oversight and monitoring of the clinical study in compliance with GCP and associated guidance materials. These safety monitoring functions and the oversight of such activities are distinct from the requirement for study review and approval by an IRB or IEC.

The SC is an independent body of experts that serves in an advisory capacity to the Sponsor to ensure that clinical trial participants are not exposed to unreasonable or unnecessary risks. Collectively, the SC will have methodological and clinical expertise relevant to the study design and population. SC membership will begin before the start of the clinical trial and last for its duration.
Core members of the SC will not participate in the trial as Investigators or sub-investigators, as members of any team otherwise participating in the trial, or in any other capacity that may compromise their privileged activities on the SC. Neither members of the SC nor their immediate families will have a direct financial interest in the Sponsor or an interest that is dependent on the outcome of the trial. To be considered for SC membership, all candidates must disclose all actual or potential conflicts of interest, including any financial interests in, or research activity on a competing product. SC members will be compensated at an appropriate market rate for time spent reviewing, discussing, and attending the meetings. The Sponsor will also reimburse SC members for any out-of-pocket travel expenses required for attendance at the meetings. Aside from the above, SC members will receive no additional compensation for their membership on the committee.
8 Statistical Plan

The Sponsor or its designee will be responsible for data collection and editing, reviewing and validating all the information in the eCRFs, statistical analysis, and generation of the clinical study reports.

The primary analysis and all planned secondary and exploratory analyses will be performed after all subjects have reached 12 months of age or have died or withdrawn from the study. All formal statistical conclusions will be drawn based on these analyses.

Final analyses will also be performed after all subjects have completed treatment in the study (up to 5 years) or have died or withdrawn from the study. These analyses will be considered supportive rather than confirmatory.

Prior to locking the database for each of the above-mentioned analyses, all data editing will be complete and decisions regarding the evaluability of all subject data for inclusion in the statistical analysis will be made. The rationale for excluding any data from the statistical analyses will be prospectively defined, and classification of all or part of a subject’s data as non-evaluable will be completed and documented before the entire database is locked.

8.1 General Considerations

All data will be presented in listings, and summary tables and/or graphs will be provided, as appropriate. Unless otherwise noted, all tabulations for efficacy endpoints will be presented for subjects in the Primary Efficacy Analysis Set and tabulations for other endpoints will be presented for subjects in the Full Analysis Set (FAS). Descriptive summary statistics (n, mean, median, standard deviation, minimum and maximum) will be calculated for the continuous variables. Shift tables and/or frequencies and percentages will be produced for the categorical variables. When percentages are reported, the number of treated subjects will be used as the denominator. As noted, 95% two-sided confidence intervals (CIs) will be calculated around the estimates based on the exact binomial distribution for binomial endpoints and the t-distribution for continuous endpoints.

Baseline will be defined as the last measurement prior to the first infusion of sebelipase alfa. (Note: For exploratory analyses, the first available measurement after initiation of treatment may be used as baseline if a pretreatment measurement is unavailable.) Survival rates will be based on the age of the subject. Other endpoints, unless otherwise noted, will be based on exposure (i.e., duration of time since the first infusion of sebelipase alfa).

Details of the planned analyses and statistical methodologies will be provided in a separate Statistical Analysis Plan (SAP).

8.2 Determination of Sample Size

Approximately 8 subjects who meet the requirements for inclusion in the Primary Efficacy Analysis Set (i.e., subjects whose first dose is on or before the age of 8 months) will be enrolled in this study. Additional subjects who meet the same entry criteria, but are between 8 and 24 months on the date of first dose, may be enrolled and followed for safety information.
This sample size was selected to facilitate comparison with natural history study (LAL-1-NH01) in patients with early onset LAL Deficiency. An analysis of preliminary data from study LAL-1-NH01 shows that, of the 18 patients who met growth failure criteria and had known date of death, only one patient survived past 12 months of age. (Note: Of these 18 patients, 5 had received a hematopoietic stem cell transplant and one had received a liver transplant.) An exact 95% CI for survival past 12 months of age in these patients is (0.14%, 27.29%). An analysis of survival, beginning on the date that growth failure criteria were met, indicated no relationship between age at onset of growth failure and survival past onset of growth failure. Thus, if the lower limit of an exact 95% CI for the 12-month survival rate in the current study is greater than 27.29%, there would be statistical evidence that the rate of 12-month survival in the current study is superior to that in study LAL-1-NH01 for a similar patient population. For the current study, if 8 subjects are included in the Primary Efficacy Analysis Set and 6 of these subjects survive to 12 months of age, the exact 95% CI for 12-month survival would be (34.91%, 96.81%), with the lower limit exceeding the upper limit of the CI for study LAL-1-NH01.

8.3 Analysis Sets
The following analysis sets will be defined:

Full Analysis Set
The FAS will include all subjects who received any amount of IMP.

Primary Efficacy Analysis Set
The Efficacy Analysis Set will include subjects in the FAS who were no older than 8 months of age on the date of the first infusion of sebelipase alfa.

PK Analysis Set
The PK Analysis Set will include all available sebelipase alfa serum concentration data for subjects who received at least one complete infusion of IMP in this study.

Per Protocol Analysis Set
The Per Protocol Set (PPS) will include subjects in the Primary Efficacy Analysis Set who, in addition, receive at least 4 complete infusions of sebelipase alfa. This set will be used for sensitivity analyses of efficacy endpoints.

8.4 Demographics and Baseline Characteristics
Demographics and baseline characteristics will be listed for each subject and tabulated. Chronological age will be reported in months to one decimal (xx.x months).

8.5 Subject Accountability
Data from all subjects who are enrolled (i.e., treated) in the study will be included in the summary of subject accountability. The frequency and percentage of subjects who are enrolled in the study, discontinued from the study, and completed the study, along with reasons for discontinuation, will be summarized.
8.6 **Study Treatment Usage and Compliance**

Number of weeks in the study and number of study infusions received by subjects will be summarized. The number (percent) of subjects who receive all study infusions ‘per protocol’ (i.e., subjects without missed infusions or infusion interruptions or rate changes) will be provided. A listing will be provided that summarizes sebelipase alfa exposure by subject, and date of first dose and total number of doses (by dose level) of sebelipase alfa under study LAL-CL03.

8.7 **Efficacy Analysis**

Efficacy will be analyzed for the Primary Efficacy Analysis Set. If the PPS is not identical to the Primary Efficacy Analysis Set (i.e., if at least one patient in the Primary Efficacy Analysis Set is excluded from the PPS), efficacy analyses will be repeated for the PPS.

The primary efficacy endpoint is the proportion of subjects surviving to 12 months of age. It is not anticipated that any subjects will be lost to follow-up prior to 12 months of age, but a subject who is not confirmed to have survived to 12 months of age will not be considered to have met the primary endpoint. As a complementary analysis, Kaplan-Meier survival curves of survival since birth and survival since first dose of IMP will be presented.

Survival at 18 and 24 months of age will be analyzed as described for the primary endpoint. Median age at death will also be calculated. A Kaplan-Meier estimate of median survival past first dose of IMP will be computed.

Estimated survival rates and median age at death derived from this study will be compared to rates/times reported in the literature, and will be discussed in conjunction with information derived from a natural history study in a similar patient population (study LAL-1-NH01).

Anthropometric indicators of growth, standardized by age and gender in accordance with the methodology described by the WHO and using WHO growth charts will be listed by study time point as observed values and as changes from baseline. Change from baseline in anthropometric data will be tabulated as continuous data. In addition, the percentages of subjects who meet criteria for underweight, stunting, and wasting will be tabulated for each timepoint. For anthropometric indicators of growth, age will be adjusted for prematurity if gestational age is <37 weeks and the subject is under 12 months of age. The adjustment will be made such that corrected age = chronological age minus the number of months premature.

Change and/or percent changes from baseline in AST, ALT, and serum ferritin will be tabulated for each evaluation timepoint.

A subject will be considered to have achieved transfusion-free hemoglobin normalization (TFHN) if the subject meets all of the following criteria:

1. Has two post-baseline measurements of hemoglobin at least 4 weeks apart that are both above the age-adjusted lower limit of normal (LLN);
2. Has no known additional measurements of hemoglobin that are below the age-adjusted LLN during the (minimum) 4-week period; and
3. Had no transfusions during the (minimum) 4-week period, and also no transfusions for 2 weeks prior to the first hemoglobin measurement in the (minimum) 4-week period. If all 3 criteria are met, the subject will be considered to have achieved TFHN on the date of the first hemoglobin assessment in the 4-week period. The proportion of subjects who achieve TFHN will be summarized and, if sufficient data are available, a summary of time to TFHN will be created.

A subject who is transfusion-free beginning at Week 6 will be considered to have maintained transfusion-free normal hemoglobin if, regardless of baseline hemoglobin value, the subject has no abnormally low hemoglobin values beginning at Week 8 of the study and continuing for at least 13 weeks (3 months). The proportion of subjects who have maintained transfusion-free normal hemoglobin will be summarized.

The Denver II total score and functional area scores will be derived from the questionnaire in accordance with the Technical Manual and compared to appropriate demographic norms. The total score and functional area scores will be summarized as continuous data and according to the classification as to whether the subject displays abnormal/normal development (Polat, 2010, Pediatr Int).

Shift tables will be used to tabulate dietary changes, including discontinuation of a low-fat/low-cholesterol diet and/or introduction of an unrestricted age-appropriate diet. Observed values and changes and/or percent changes from baseline in other exploratory efficacy endpoints will be tabulated for each evaluation timepoint.

### 8.8 Safety Analysis

Safety will be analyzed for the FAS.

#### 8.8.1 Adverse Events

All reported AEs will be listed from the start of dosing with sebelipase alfa to the end of participation in this study. Separate listings of SAEs and IARs will also be provided. The numbers and percentages of subjects experiencing any AE, any SAE, any IAR, any related AE, any related SAE, and discontinuations due to an AE will be tabulated.

The frequency of treatment-emergent AEs, SAEs, and IARs by system organ class SOC and preferred term (coded using Medical Dictionary for Regulatory Activities [MedDRA®] version 14 or higher) will be tabulated. Frequencies will also be presented by the classifications of severity and causality. In addition, frequency of AEs, SAEs, and IARs will be presented for time periods spanning the entire course of treatment with sebelipase alfa: from the start of dosing with sebelipase alfa in this study to 3 months after the first dose, >3 to 6 months, >6 to 12 months, >12 to 18 months, >18 to 24 months and >24 months. As appropriate, additional listings, summary tables and graphics will be generated to evaluate IAR frequency and severity over time. A listing of subjects who withdraw from the study due to AEs will be presented, and the incidence of AEs leading to study discontinuation will be summarized.
8.8.2 Clinical Laboratory Tests
Observed measurements and changes from baseline to each study timepoint in clinical laboratory data will be summarized. Clinically significant abnormal values will be listed. Frequencies of abnormal values relative to the laboratory normal range and clinically significant abnormal values will be tabulated for each study timepoint. Shift tables may also be provided.

The percentage of subjects who become ADA positive, time to ADA positivity, median and peak IgG antibody titer, time to peak IgG antibody titer, and percentage of subjects who tolerize will be summarized; IgG antibody titer values will be tabulated at each study visit using summary statistics appropriate to the data.

8.8.3 Other Safety Data
Changes in vital signs from pre-infusion values to each time point during or post-infusion will be summarized. Abnormal findings/values for physical examinations, vital signs, and ECGs will also be listed.

Concomitant medication/treatment data will be coded using the WHO-DRUG dictionary. All data will be listed, and the percentages of subjects receiving each concomitant medication/treatment will be tabulated.

8.9 Pharmacokinetics
Pharmacokinetics will be analyzed for the PK Analysis Set. $C_{\text{max}}$ will be recorded from direct observation, and CL will be derived by non-compartmental analysis. PK parameters will be summarized by dose of sebelipase alfa, if applicable.

8.10 Pharmacodynamic Analysis
Potential disease-related biomarkers will be listed, and observed values and changes and/or percent changes from baseline will be summarized at available timepoints.

8.11 Other Statistical Issues

8.11.1 Significance Levels
No formal hypothesis tests are planned. P-values, where presented, will be based on a 2-sided alpha of 0.05 and are intended to guide clinical judgment and interpretation of the data.

8.12 Subgroup Analyses
The impact of ADAs on safety, efficacy, PK, and PD endpoints will be explored descriptively. As subject numbers permit, other subgroup analyses of interest may be performed. These may include, but are not limited to age, gender, and race.

8.13 Missing or Invalid Data
All data will be analyzed as they were collected in the database.
8.14 Interim Analysis
No interim analyses are planned.

9  Data Handling and Record Keeping

9.1 Confidentiality
Information about study subjects will be kept confidential and managed according to the requirements of applicable local regulations.

9.2 Source Documents
Source data is all information, original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents. Examples of these original documents, and data records include: hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories, and at medico-technical departments involved in the clinical trial.

9.3 Case Report Forms
Required data for this study will be captured on eCRFs via electronic data capture unless otherwise specified in this document. Except for data points for which the protocol indicates that the eCRF may serve as source documentation, data are to be obtained from the subject’s source documents and then entered into the eCRF by authorized site personnel. Clinical data that are not recorded on the eCRF will be captured and transferred to the Sponsor or its designee.

9.4 Records Retention
It is the Investigator’s responsibility to retain study essential documents for at least 2 years after the last approval of a marketing application in their country and until there are no pending or contemplated marketing applications in their country or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period if required by an agreement with the Sponsor. In such an instance, it is the responsibility of the Sponsor to inform the Investigator/institution as to when these documents no longer need to be retained.
10 Study Monitoring, Auditing, and Inspecting

10.1 Study Monitoring Plan
This study will be monitored according to the study monitoring plan. The Investigator will allocate adequate time for such monitoring activities. The Investigator will also ensure that the monitor or other compliance or quality assurance reviewer is given access to all the above noted study-related documents and study related facilities (e.g. pharmacy, diagnostic laboratory, etc.), and has adequate space to conduct the monitoring visit.

10.2 Auditing and Inspecting
The Investigator will permit study-related monitoring, audits, and inspections by the IRB/IEC, the Sponsor, government regulatory authorities, and quality assurance groups of all study related documents (e.g. source documents, regulatory documents, data collection instruments, study data etc.). The Investigator will ensure the capability for inspections of applicable study-related facilities (e.g., pharmacy, diagnostic laboratory, etc.).

Participation as an Investigator in this study implies acceptance of potential inspection by government regulatory authorities and applicable compliance and quality assurance offices.
11 Ethical Considerations

This study is to be conducted according to US and international standards of GCP (FDA Title 21 part 312 and ICH guidelines), applicable government regulations and Institutional research policies and procedures.

This protocol and any amendments will be submitted to a properly constituted IRB/IEC, in agreement with local legal prescriptions, for formal approval of the study conduct. The decision of the IRB/IEC concerning the conduct of the study will be made in writing to the Investigator and a copy of this decision will be provided to the Sponsor before commencement of this study. The Investigator should provide a list of IRB/IEC members and their affiliate to the Sponsor.

Each subject's parent or legal guardian for this study will be provided a consent form describing this study and providing sufficient information for the subject's parent or legal guardian to make an informed decision about their child’s participation in this study. This consent form will be submitted with the protocol for review and approval by the IRB/IEC for the study. The formal consent of a subject, using the IRB/IEC-approved consent form, must be obtained before that subject undergoes any study procedure. The consent form must be signed by the subject’s parent or legal guardian, and the Investigator-designated research professional obtaining the consent.

Any changes in the study protocol, such as changes in the study design, objectives or endpoints, inclusion and exclusion criteria, and/or procedures (except to eliminate an immediate hazard) will be implemented only after the mutual agreement of the Investigator and the Sponsor or designee. All protocol changes must be documented in protocol amendment(s). Protocol amendment(s) must be signed by the Investigator and approved by the IRB/IEC prior to implementation. Any changes in study conduct that result from a pending amendment will be considered protocol deviations until IRB/IEC approval is granted. Documentation of IRB/IEC approval must be returned to the Sponsor or designee.
12 Clinical Study Report and Publication Plan

A clinical study report will be produced after all subjects have reached 12 months of age or have died or withdrawn from the study, and will include all available subject data through 12 months of age or the date of death or early withdrawal. A final clinical study report will be produced after study completion, and will include cumulative subject data for the entire period of treatment in the study. A coordinating Investigator will be designated to review and sign the completed clinical study reports.

It is intended that the results from this research will be submitted to a peer-reviewed medical publication, once the study is completed, regardless of the outcome.
13 References


14 Appendices
## Appendix A: Schedule of Assessments Table 1 -- Screening through Week 24

<table>
<thead>
<tr>
<th>Assessments</th>
<th>Screening</th>
<th>Screening to Week 24,*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Week 0</td>
<td>Week 1, 6, 10, 14 Week 2 Week 3 Week 4 Week 5, 7, 11, 13 Week 8, 16 Week 9, 15 Week 12 Week 17, 18, 19, 21, 23 Week 20 Week 22 Week 24</td>
</tr>
<tr>
<td></td>
<td>± 2 days</td>
<td>± 2 days</td>
</tr>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Inclusion/Exclusion</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Medical/Family History</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Physical Exam</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Photographs</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Anthropometrics</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Weight</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Recumbent length or height, and</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>abdominal circumference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head and mid-upper arm</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>circumference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital Signs</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>12-lead ECG</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Denver II</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Abdominal Ultrasound</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Abdominal MRI</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Liver Biopsy</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Clinical LabTests</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Exploratory Biomarkers</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>DNA Sample (subject)</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>DNA Sample (parents)</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>PK Sample</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>PBMC LAL Activity</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>DBS LAL Activity</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Sebelipase alfa Dosing</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Anti-drug Antibody</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Adverse Events</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

* All visits will be calculated from Week 0; consecutive infusions must be administered at least 5 days apart.

P Pre-dose

1 Abdominal MRI should be considered in subjects receiving general anesthesia and/or sedation for other procedures. The MRI should be scheduled at least 3 months after the preceding MRI assessment. If an MRI cannot be performed, an Ultrasound will be performed.
For the subjects who are stable enough to be treated on an outpatient basis, safety follow-up assessments for AEs will be conducted by telephone 24 hours following the first 2 infusions of 0.35 mg·kg⁻¹ qw, 1 mg·kg⁻¹ qw, and, if applicable, 3 mg·kg⁻¹ qw and 5 mg·kg⁻¹ qw.
## Appendix A: Schedule of Assessments Table 2 -- Week 25 through 156 (Year 3)*

<table>
<thead>
<tr>
<th>Assessments</th>
<th>Every week</th>
<th>Week 32 ± 2 days</th>
<th>Week 36 ± 2 days</th>
<th>Week 40 ± 2 days</th>
<th>Week 48 ± 2 days</th>
<th>Week 60 ± 2 days</th>
<th>Week 72 ± 2 days</th>
<th>Week 84 ± 2 days</th>
<th>Week 96 ± 2 days</th>
<th>Week 108 ± 2 days</th>
<th>Week 120 ± 2 days</th>
<th>Week 132 ± 2 days</th>
<th>Week 144 ± 2 days</th>
<th>Week 156 ± 2 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical Exam</td>
<td></td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
</tr>
<tr>
<td>Photographs</td>
<td></td>
<td></td>
<td>Δ X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anthropometrics</td>
<td></td>
<td></td>
<td>Δ X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight</td>
<td></td>
<td>Δ X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recumbent length or height, and abdominal circumference</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Head and mid-upper arm circumference</td>
<td></td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
</tr>
<tr>
<td>Vital Signs</td>
<td></td>
<td>Δ X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-lead ECG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Denver II 1</td>
<td></td>
<td></td>
<td>Δ X</td>
<td>Δ X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal Ultrasound 1</td>
<td></td>
<td>Δ X</td>
<td></td>
<td></td>
<td>Δ X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal MRI 1,2</td>
<td></td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
</tr>
<tr>
<td>Liver Biopsy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Lab Tests 3</td>
<td></td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
</tr>
<tr>
<td>Exploratory Biomarkers 3</td>
<td></td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
</tr>
<tr>
<td>PK Sample 3</td>
<td></td>
<td>Δ X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sebelipase alfa Dosing 4</td>
<td></td>
<td>Δ X</td>
<td></td>
<td></td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
</tr>
<tr>
<td>Anti-drug Antibody 3</td>
<td></td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
<td>Δ X</td>
</tr>
<tr>
<td>Adverse Events 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant Therapies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* All visits will be calculated from Week 0; consecutive infusions must be administered at least 5 days apart.

**Pre-dose**

1 Assessments can be performed (±15) days of scheduled visit.

2 Abdominal MRI should be considered in subjects receiving general anesthesia and/or sedation for other procedures. The MRI should be scheduled at least 3 months after the preceding MRI assessment. If an MRI cannot be performed, an ultrasound will be performed.

3 If blood volume is limited, refer to Section 5.1.11 for tiered assessments.

4 Subjects may transition to an every other week dosing schedule after 96 weeks if on a stable dose for at least 24 weeks.
For the subjects who are stable enough to be treated on an outpatient basis, safety follow-up assessments for AEs will be conducted by telephone 24 hours following the first 2 infusions of 0.35 mg kg⁻¹ qw, 1 mg kg⁻¹ qw, and, if applicable, 3 mg kg⁻¹ qw and 5 mg kg⁻¹ qw.

### Appendix A: Schedule of Assessments Table 3 – Week 157 through 260 (Year 5)*

<table>
<thead>
<tr>
<th>Assessments</th>
<th>Week 157 - Week 260</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Every week</td>
</tr>
<tr>
<td></td>
<td>Week 157-168</td>
</tr>
<tr>
<td></td>
<td>Week 169-170</td>
</tr>
<tr>
<td></td>
<td>Week 171-180</td>
</tr>
<tr>
<td></td>
<td>Week 181-192</td>
</tr>
<tr>
<td></td>
<td>Week 193-204</td>
</tr>
<tr>
<td></td>
<td>Week 205-216</td>
</tr>
<tr>
<td></td>
<td>Week 217-228</td>
</tr>
<tr>
<td></td>
<td>Week 229-240</td>
</tr>
<tr>
<td></td>
<td>Week 241-252</td>
</tr>
<tr>
<td></td>
<td>Week 253-260</td>
</tr>
<tr>
<td>Physical Exam</td>
<td>X</td>
</tr>
<tr>
<td>Photographs</td>
<td>X</td>
</tr>
<tr>
<td>Anthropometrics</td>
<td>X</td>
</tr>
<tr>
<td>Weight</td>
<td>X</td>
</tr>
<tr>
<td>Recumbent length or height, and abdominal</td>
<td>X</td>
</tr>
<tr>
<td>circumference</td>
<td>X</td>
</tr>
<tr>
<td>Vital Signs</td>
<td>X</td>
</tr>
<tr>
<td>12-lead ECG</td>
<td>X</td>
</tr>
<tr>
<td>Denver II ²</td>
<td>X</td>
</tr>
<tr>
<td>Abdominal Ultrasound ²</td>
<td>X</td>
</tr>
<tr>
<td>Abdominal MRI ², ³</td>
<td>X</td>
</tr>
<tr>
<td>Liver Biopsy</td>
<td>Optional after at least 1 year of treatment</td>
</tr>
<tr>
<td>Clinical LabTests ⁴</td>
<td>X</td>
</tr>
<tr>
<td>Exploratory Biomarkers ⁴</td>
<td>X</td>
</tr>
<tr>
<td>Sebelipase alfα Dosing ⁵</td>
<td>X</td>
</tr>
<tr>
<td>Anti-drug Antibody ⁴</td>
<td>X</td>
</tr>
<tr>
<td>Adverse Events ⁵</td>
<td>CONTINUOUS</td>
</tr>
<tr>
<td>Concomitant Therapies ⁶</td>
<td>CONTINUOUS</td>
</tr>
</tbody>
</table>

*All visits will be calculated from Week 0; consecutive infusions must be administered at least 5 days apart.

1 The follow-up / early withdrawal visit will be conducted 30 (+7) days after the last dose of IMP.
2 Assessments can be performed (±15) days of scheduled visit.
3 Abdominal MRI should be considered in subjects receiving general anesthesia and/or sedation for other procedures. The MRI should be scheduled at least 3 months after the preceding MRI assessment. If an MRI cannot be performed, an Ultrasound will be performed.
4 If blood volume is limited, refer to Section 5.1.11 for tiered assessments.
5 Subjects may transition to an every other week dosing schedule after 96 weeks if on a stable dose for at least 24 weeks.
For the subjects who are stable enough to be treated on an outpatient basis, safety follow-up assessments for AEs will be conducted by telephone 24 hours following the first 2 infusions of 0.35 mg·kg\(^{-1}\) qw, 1 mg·kg\(^{-1}\) qw, and, if applicable, 3 mg·kg\(^{-1}\) qw and 5 mg·kg\(^{-1}\) qw.
### Appendix B: Diagnosis and Recommendations for Management of Infusion Associated Reactions

<table>
<thead>
<tr>
<th>Symptoms may include but are not limited to:</th>
<th>Actions in accordance with institutional standard of care</th>
</tr>
</thead>
</table>
| **Mild**  
  **Common**  
  - Hyperemia (Flushing)  
  - Lightheadedness  
  - Nausea  
  - Mild chest discomfort (tightness)  
  **Less Common**  
  - Fever and/or shivering  
  - Palpitations  
  - Headache  
  - Irritability (especially in young children)  | - Slow infusion rate by 50%  
- Administer oral anti-pyretic and/or anti-histamine  
- Decrease infusion rate by a further 25% if symptoms persist  
- Increase infusion time  
- If the event resolves, the infusion should continue at reduced rate for a minimum of 30 minutes before infusion is increased to 75% of original rate. If subject tolerates infusion at 75% of the original rate for at least 30 minutes the original rate may be restored for the remainder of the infusion.  
- If symptoms continue despite rate reduction stop infusion  
- Pre-treat with oral antihistamine and antipyretic prior (approximately 1.5h) to next infusion  
  - e.g., diphenhydramine (1 mg/kg po) and acetaminophen (15 mg/kg po)  |
| **Moderate Reaction**  
  - Hyperemia (flushing)  
  - Chest discomfort  
  - Itching and/or raised urticarial rash  
  - Severe headache  
  - Gastro intestinal symptoms, vomiting, diarrhoea, abdominal cramping.  | - Stop infusion  
- Give antihistamine IV and consider IV steroids  
- Give any prescribed inhaler treatment if appropriate  
- If the event has resolves, the infusion may continue at reduced rate of 50% of the original for a minimum of 30 minutes before infusion is increased to 75% of original rate. If patient tolerates infusion at 75% of the original rate for at least 30 minutes the original rate may be restored for the remainder of the infusion.  
- Pre-treat with oral antihistamine and antipyretic prior to next infusion  
- Collect serum sample for tryptase 1-3 hours after the IAR onset and another serum sample for tryptase and ADA during the next study visit (> 4 days after the IAR) prior to the infusion.  
- Skin testing may be considered.  |
### Severe Reaction

- Clinically significant cardiovascular effects: e.g., hypertension or hypotension defined as a decline approaching 20-30% of their preinfusion value without alternative etiology, agitation, pain, fluid overload, dehydration
- Respiratory symptoms: Significant shortness of breath, stridor, wheezing, laryngeal oedema, swelling of tongue.
- Cardiac Arrhythmias
- Anaphylactic/Anaphylactoid shock with hypotension and circulatory collapse.

### Immediate Measures

- Stop Infusion
- Give oxygen, if available
- Give epinephrine (adrenaline) IM or inhaled
- Give antihistamines IV and steroids IV
- Collect serum sample for tryptase 1-3 hours after the IAR onset and another serum sample for tryptase and ADA during the next study visit (≥ 4 days after the IAR) prior to the infusion.
- Skin testing may be considered
- Dosing of the subject will be suspended until the Safety Committee has completed the review of the IAR and any other relevant safety data (Section 6.5)
Appendix C: Dose Modification and Stopping Rules for LAL-CL03 Study

In the absence of an approved grading scale that can be applied to specific patient populations, this protocol will apply the National Cancer Institute Common Toxicity Classification of Adverse Events (NCI CTCAE), version 4.0 or higher. (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf).

The following stopping rules apply to the decision to pause dosing in individual subjects:

For IARs (refer to the definition in Section 6.5), the following stopping rules will apply:

- Subjects who develop a Grade 3 (severe) or higher IAR must stop treatment until their information is reviewed by the SC. Dosing with alterations to the infusion regimen (e.g., pretreatment and/or slowing the rate of infusion) may resume once the SC and the Sponsor approve. Confirmation may also be sought from regulatory authorities prior to resuming dosing.